



# **Prior Authorization Requirements**

**Effective: 01/01/2018**

CommuniCare Advantage Cal MediConnect Plan (Medicare-Medicaid Plan) is a health plan that contracts with both Medicare and Medi-Cal to provide benefits of both programs to enrollees.

This is not a complete list of drugs covered by our plan. For a complete and current listing, please call Member Services 24 hours a day, seven days a week at 1-888-244-4430 or TTY 1-855-266-4584 or visit [www.chgsd.com](http://www.chgsd.com). This is not a complete list of all formulary alternatives covered by the Part D sponsor for the drug you have selected.

# ABALOPARATIDE

## Products Affected

- Tymlos

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	ONE OF THE FOLLOWING: (1) HIGH RISK FOR FRACTURES DEFINED AS ONE OF THE FOLLOWING: HISTORY OF OSTEOPOROTIC (I.E., FRAGILITY, LOW TRAUMA) FRACTURE(S). 2 OR MORE RISK FACTORS FOR FRACTURE (E.G., HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS SUCH AS NAFARELIN, ETC.). NO PRIOR TREATMENT FOR OSTEOPOROSIS AND FRAX SCORE OF AT LEAST 20% FOR ANY MAJOR FRACTURE OR OF AT LEAST 3% FOR HIP FRACTURE. (2) UNABLE TO USE ORAL THERAPY (I.E., UPPER GASTROINTESTINAL PROBLEMS UNABLE TO TOLERATE ORAL MEDICATION, LOWER GASTROINTESTINAL PROBLEMS UNABLE TO ABSORB ORAL MEDICATIONS, TROUBLE REMEMBERING TO TAKE ORAL MEDICATIONS OR COORDINATING AN ORAL BISPHOSPHONATE WITH OTHER ORAL MEDICATIONS OR THEIR DAILY ROUTINE). (3) ADEQUATE TRIAL OF, INTOLERANCE TO, OR A CONTRAINDICATION TO BISPHOSPHONATES (E.G., ALENDRONATE, RISEDRONATE, IBANDRONATE).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

# ABATACEPT IV

---

## Products Affected

- Orencia (with maltose)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST
<b>Coverage Duration</b>	INITIAL: RA: 6 MOS. JIA: 4 MOS. PSA: 12 MOS. RENEWAL: 12 MOS ALL INDICATIONS
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. JUVENILE IDIOPATHIC ARTHRITIS (JIA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

# ABATACEPT SQ

## Products Affected

- Orenzia
- Orenzia ClickJect

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. JUVENILE IDIOPATHIC ARTHRITIS (JIA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

# ABEMACICLIB

---

## Products Affected

- Verzenio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TRIAL OF OR CONTRAINDICATION TO IBRANCE (PALBOCICLIB) WHEN REQUEST IS FOR COMBINATION THERAPY WITH FULVESTRANT FOR HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER.

# ABIRATERONE

---

## Products Affected

- Zytiga

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ACALABRUTINIB

---

## Products Affected

- Calquence

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ACETAMINOPHEN OTC

## Products Affected

- ACETAMINOPHEN 160 MG/5 ML ELX
- CHILD ACETAMINOPHEN 80 MG/2.5 ML ORAL SYRINGE 50'S, U-D, ORAL SYR
- CHILD PAIN-FEVER 160 MG/5 ML
- CVS CHILD PAIN RLF 160 MG/5 ML CHILDREN'S, A/F
- INFANT PAIN RELV 80 MG/0.8 ML A/F, GLUTEN-FREE
- INFANT'S PAIN RELIEF SUSP DROP
- LITTLE REMEDIES FEVER 160 MG/5 A/F,D/F, GLUTEN-FREE
- MAPAP 160 MG/5 ML LIQUID
- MAPAP 160 MG/5 ML SUSPENSION
- NON-ASPIRIN CHILD'S DROPS
- NORTEMP 80 MG/0.8 ML DROP
- PEDIACARE FEVER REDUCER SUSP
- PV CHILDREN'S NON-ASA LIQ
- PV INFANT NON-ASA 80 MG/0.8 ML ASPIRIN FREE, A/F
- RA INFANT FEVER-PAIN REL SUSP
- RA NON-ASPIRIN 160 MG/5 ML CHILDREN'S, CHERRY
- SILAPAP INFANT'S DROPS INFANT'S

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	RESTRICTED TO INDIVIDUALS YOUNGER THAN 21 YEARS OF AGE FOR THE LIQUID AND DROPS ONLY.



# ADALIMUMAB

## Products Affected

- Humira
- Humira Pediatric Crohn's Start
- Humira Pen
- Humira Pen Crohn's-UC-HS Start
- Humira Pen Psoriasis-Uveitis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: CURRENT WEIGHT. PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL:RA:6 MO PSA/AS:4 MO PJIA:5 MO PSO/CD/UC/HS:3 MO UVEITIS:6 MO RENEWAL:12 MO ALL INDICATIONS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS: TRIAL OF FORMULARY AGENTS NOT REQUIRED. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF ONE OF THE FOLLOWING CONVENTIONAL THERAPIES SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE.</p>

# AFATINIB DIMALEATE

---

## Products Affected

- Gilotrif

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ALECTINIB

---

## Products Affected

- Alecensa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ALEMTUZUMAB - LEMTRADA

---

## Products Affected

- Lemtrada

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 1 MONTH. RENEWAL: 12 MONTHS.
Other Criteria	TRIAL WITH TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR GLATIRAMER. RENEWAL REQUESTS FOR ALEMTUZUMAB REQUIRE THAT AT LEAST 12 MONTHS HAVE ELAPSED SINCE RECEIVING THE FIRST COURSE OF LEMTRADA. PATIENTS ARE LIMITED TO TWO COURSES OF THERAPY WITH LEMTRADA WITHIN A LIFETIME.

# ALIROCUMAB

---

## Products Affected

- Praluent Pen

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS OF AGE AND OLDER.
<b>Prescriber Restrictions</b>	CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>MUST HAVE A LDL CHOLESTEROL LEVEL GREATER THAN 100MG/DL WHILE ON MAXIMAL DRUG TREATMENT FOR THE PAST 2 MONTHS AND ONE OF THE FOLLOWING DIAGNOSES: (1) HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) DETERMINED BY SIMON BROOME DIAGNOSTIC CRITERIA FOR HEFH OR A SCORE OF 6 OR GREATER ON THE DUTCH LIPID NETWORK CRITERIA FOR HEFH OR (2) HISTORY OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AS DOCUMENTED BY PHYSICIAN ATTESTATION. PATIENT MUST NOT HAVE CONCURRENT USE OF REPATHA OR OTHER PCSK9 AGENT. INITIAL THERAPY: FOR STATIN TOLERANT PATIENTS: MUST HAVE TAKEN ATORVASTATIN OR ROSUVASTATIN FOR THE PAST 2 MONTHS. FOR STATIN INTOLERANT PATIENTS: DOCUMENTATION OF STATIN INTOLERANCE BY ONE OF THE FOLLOWING: (1) PHYSICIAN ATTESTATION, (2) PATIENT HAS TRIED ROSUVASTATIN, ATORVASTATIN, OR STATIN THERAPY AT ANY DOSE AND HAS EXPERIENCED SKELETAL-MUSCLE RELATED SYMPTOMS (E.G., MYOPATHY). PATIENTS WITH CONTRAINDICATIONS TO STATINS INCLUDING ACTIVE DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT OR HYPERSENSITIVITY REACTIONS WILL BE APPROVED FOR PRALUENT THERAPY WITHOUT REQUIREMENT OF DOCUMENTATION OF STATIN INTOLERANCE. RENEWAL CRITERIA: RECEIVING PRIOR PRALUENT THERAPY FOR THE PAST 6 MONTHS AND NO CLAIMS FOR REPATHA, JUXTAPID, OR KYNAMRO SINCE PRALUENT APPROVAL.</p>

# AMANTADINE

---

## Products Affected

- Gocovri oral capsule, extended release 24hr  
137 mg, 68.5 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# ANAKINRA

---

## Products Affected

- Kineret

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA: 6 MONTHS NOMID/CAPS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA.

# ANTI-HISTAMINES AND DECONGESTANTS

---

## Products Affected

- 12 HOUR RELIEF TABLET
- 25DPH-7.5PEH LIQUID
- ALA-HIST IR 2 MG TABLET
- ALA-HIST PE TABLET
- ALAVERT 10 MG ODT
- ALLER-CHLOR 2 MG/5 ML SYRUP
- ALLER-CHLOR 4 MG TABLET
- ALLERGY 4 MG TABLET
- ALLERHIST-1 1.34 MG TABLET
- AMBI 60PSE-4CPM TABLET
- APRODINE TABLET
- BROTOPP LIQUID
- CETIRIZINE HCL 1 MG/ML SOLN CHILDREN, S/F, GRAPE (OTC)
- CETIRIZINE HCL 10 MG CHEW TAB CHILDREN'S, OUTER, U-D
- CETIRIZINE HCL 10 MG TABLET
- CETIRIZINE HCL 5 MG TABLET
- CHILD ALLEGRA ALLERGY 30 MG/5 ML SUSPENSION
- CHILD CETIRIZINE 5 MG CHEW TAB
- CHILD DOMETUSS-DA LIQUID
- CHILD LORATADINE 5 MG/5 ML SYR GRAPE, S/F
- CHILD TRIAMINIC COLD & ALLERGY
- CHILD WAL-ITIN 5 MG/5 ML SOLN
- CHILD WAL-TAP COLD-ALLERGY ELX
- CHILD WAL-ZYR 1 MG/ML SOLUTION CHERRY
- CHILD'S ALLER-TEC 1 MG/ML SOLN
- CHILD'S WAL-ZYR 10 MG CHEW TAB
- CHILDREN'S COLD & ALLERGY ELXR A/F
- CHILDREN'S SILFEDRINE LIQ
- CHILDREN'S WAL-FEX 30 MG/5 ML
- CHILDS SUDAFED 15 MG/5 ML LIQ NON-DROWSY, A/F, S/F
- CHLORHIST 4 MG TABLET
- CHLORPHENIRAMINE ER 12 MG TAB
- Cold-Allergy-Sinus
- CONEX SOLUTION
- CONEX TABLET
- CVS ALLERGY-D TABLET
- CVS CHILD ALLERGY 10 MG CHW TB 24 HR, INDOOR/OUTDOOR
- CVS COLD & COUGH NIGHTTIME LIQ
- CVS MOTION SICKNESS RELIEF TAB CHEWABLE TABLET
- CVS NOSE DROPS
- DAILYHIST-1 1.34 MG TABLET
- DALLERGY 1-5 MG TABLET
- DAYHIST ALLERGY 1.34 MG TABLET 12 HR RELIEF
- DAYHIST TABLET
- DIMAPHEN ELIXIR A/F, GRAPE, GLUTEN-F
- DIMETAPP COLD & CONGEST LIQUID
- DRAMAMINE LESS DROWSY 25 MG TB
- ED A-HIST LIQUID (OTC)
- ED CHLORPED DROPS
- ED CHLORPED JR SYRUP
- ED-A-HIST 4 MG-10 MG TABLET
- EQ ALLERGY & SINUS RELIEF TAB
- EQL ALLERGY RELIEF 10 MG ODT NON-DROWSY
- FEXOFENADINE HCL 180 MG TABLET 24 HOUR, NON-DROWSY (OTC)
- FEXOFENADINE HCL 30 MG/5 ML
- FEXOFENADINE HCL 60 MG TABLET INDOOR/OUTDOOR (OTC)
- HISTEX-PE SYRUP
- KRO CHILD NITE TIME COLD & CGH

- LOHIST-D LIQUID
- LORATADINE 10 MG TABLET
- MECLIZINE 12.5 MG CAPLET CAPLET (OTC)
- MECLIZINE 25 MG TABLET (OTC)
- MEDI-MECLIZINE 25 MG TABLET OUTER, F/C
- MEDI-PHEDRINE 30 MG TABLET
- NASAL DECONGEST-ANTI HIST TAB
- NASAL-SINUS DECONGEST TAB
- PEDIAVENT 1 MG TABLET CHEW
- PEDIAVENT 2 MG/5 ML SYRUP
- PHENYLEPHRINE-PYRILAMINE 10-25
- PHENYLHISTINE DH LIQUID (OTC)
- PROMETHAZINE VC-CODEINE SYRUP
- PROMETHAZINE-CODEINE SYRUP
- PROMETHAZINE-DM SYRUP
- PSEUDOEPHED 30 MG/5 ML SOLN
- PSEUDOEPHEDRINE 30 MG TABLET
- PSEUDOEPHEDRINE 60 MG TABLET EX-STR, NON DROWSY (OTC)
- RA ACTA-TABS PE TABLET
- RA ALLERGY PLUS SINUS TABLET
- RA CHILD CETIRIZINE 10 MG CHEW 24 HR, INDOOR/OUTDOOR
- RA LORATADINE 10 MG TABLET NON-DROWSY
- RA MOTION SICKNESS RLF TB CHEW RASPBERRY FLAVOR
- RITIFED SYRUP
- RYMED TABLET
- SM ADULT NASAL DECONGESTANT LQ
- SM ALLERGY RELIEF 1.34 MG TAB
- SM COLD & ALLERGY TABLET
- SM NOSE DROPS
- SM SINUS AND ALLERGY TABLET MAXIMUM STRENGTH
- SUDOGEST 30 MG TABLET BOXED
- SUDOGEST 60 MG TABLET
- SUDOGEST SINUS & ALLERGY TAB
- SUPHEDRIN LIQUID
- TRAVEL SICKNESS 25 MG TAB CHEW
- TRAVEL-EASE 25 MG TABLET
- V-R TRIACTING ORANGE SYRUP
- VALU-TAPP DECONGESTANT DROP
- VAZOBID-PD SUSPENSION
- VAZOTAB 10-25 MG TABLET
- WAL-ACT D COLD & ALLERGY TAB
- WAL-DRYL-D ALLERGY & SINUS CPT
- WAL-FEX ALLERGY 180 MG TABLET
- WAL-FEX ALLERGY 60 MG TABLET
- WAL-FINATE 4 MG TABLET
- WAL-FINATE-D TABLET
- WAL-ITIN 10 MG ODT NON-DROWSY
- WAL-ITIN 10 MG TABLET NON-DROWSY, 24 HR RLF
- WAL-PHED 30 MG TABLET NON-DROWSY, MAX-STR
- WAL-PHED PE SINUS-ALLERGY TAB
- WAL-PHED SINUS AND ALLERGY TAB
- WAL-TAP ELIXIR
- WAL-ZYR 10 MG TABLET
- ZEPHREX-D 30 MG TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	N/A
<b>Other Criteria</b>	RESTRICTED TO INDIVIDUALS 2 YEARS OF AGE AND OLDER.

# ANTI-HISTAMINES AND DECONGESTANTS - DIPHENHYDRAMINE

## Products Affected

- ALER-CAPS 25 MG CAPSULE
- ALER-TAB 25 MG TABLET
- ALKA-SELTZER PLUS ALLERGY TAB
- ANTIHISTAMINE 25 MG CAPSULE
- BANOPHEN 25 MG CAPSULE
- BANOPHEN 25 MG TABLET
- BANOPHEN 50 MG CAPSULE
- BANOPHEN ALLERGY 12.5 MG/5 ML A/F
- BENADRYL ALLERGY 25 MG ULTRATB ULTRATAB
- CHILD'S BENADRYL 12.5 MG/5 ML
- COMPOZ 25 MG GELCAP
- CVS ALLERGY 25 MG TABLET
- DIPHEDRYL 12.5 MG/5 ML ELIXIR
- DIPHENHIST 12.5 MG/5 ML SOLN
- DIPHENHIST 25 MG CAPSULE
- DIPHENHIST 25 MG CAPTAB CAPTAB
- DIPHENHYDRAMINE 25 MG CAPSULE (OTC)
- GERI-DRYL 12.5 MG/5 ML LIQUID
- HM Z-SLEEP 25 MG SOFTGEL
- LORATADINE 10 MG SOFTGEL
- NYTOL 25 MG QUICKCAPS CAPLET CAPLET
- RA ALLERGY MED 25 MG CAPSULE
- RA ALLERGY MED 25 MG TABLET
- RA ALLERGY MED 25 MG TABLET COATED MINITABS
- RA SLEEP TABLET
- RA SLEEP-AID SOFTGEL
- SILADRYL 12.5 MG/5 ML LIQUID
- UNISOM 50 MG SLEEPGELS SOFTGEL
- VALU-DRYL ALLERGY MED TAB
- WAL-DRYL ALLERGY 12.5 MG/5 ML
- WAL-DRYL ALLERGY 25 MG CAPSULE
- WAL-DRYL ALLERGY 25 MG MINITAB MINITAB, COATED
- WAL-SLEEP Z 25 MG ODT
- WAL-SLEEP Z 25 MG SOFTGEL
- WAL-SOM 25 MG ODT
- WAL-SOM 50 MG SOFTGEL SOFTGEL,MAX STRENGTH

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	N/A
<b>Other Criteria</b>	RESTRICTED TO USE IN THE TREATMENT OF ALLERGIES OR ALLERGIC CONDITIONS ONLY AND TO INDIVIDUALS 2 YEARS OF AGE AND OLDER.

# ANTI-OBESITY AGENTS -PHENTERMINE

## Products Affected

- LOMAIRA 8 MG TABLET
- PHENTERMINE 15 MG CAPSULE
- PHENTERMINE 30 MG CAPSULE
- PELLETIZED
- PHENTERMINE 37.5 MG CAPSULE

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	REQUEST FOR PHENTERMINE FOR THE MANAGEMENT OF WEIGHT LOSS OR WEIGHT MANAGEMENT IS RESTRICTED TO INDIVIDUALS 17 YEARS OF AGE OR OLDER. COVERED USES ONLY FOR FDA APPROVED INDICATIONS. CRITERIA TO BE MET INCLUDE ONE OF THE FOLLOWING: A BODY MASS INDEX (BMI) OF 30 KG/M2 OR GREATER OR A BMI OF 27 KG/M2 OR GREATER AND AT LEAST ONE WEIGHT-RELATED CO-MORBIDITY SUCH AS HYPERTENSION, TYPE 2 DIABETES MELLITUS, OR HYPERLIPIDEMIA.

# APREMILAST

## Products Affected

- Otezla
- Otezla Starter

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST
<b>Coverage Duration</b>	INITIAL: PSORIATIC ARTHRITIS: 4 MONTHS. PSORIASIS: 5 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA AND ONE CONVENTIONAL THERAPY SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE.



# ASFOTASE

---

## Products Affected

- Strensiq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION, SERUM ALKALINE PHOSPHATASE (ALP) LEVEL, SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS, URINE PHOSPHOETHANOLAMINE (PEA) LEVEL, RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP)
<b>Age Restrictions</b>	PERINATAL/INFANTILE-ONSET HYPOPHOSPHATASIA (HPP): 6 MONTHS OF AGE OR YOUNGER AT HYPOPHOSPHATASIA (HPP) ONSET. JUVENILE-ONSET HYPOPHOSPHATASIA (HPP): 18 YEARS OF AGE OR YOUNGER AT HYPOPHOSPHATASIA (HPP) ONSET.
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH AN ENDOCRINOLOGIST, A GENETICIST, OR A METABOLIC SPECIALIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: FOR PATIENTS WITH PERINATAL/INFANTILE-ONSET HYPOPHOSPHATASIA (HPP), ALL OF THE FOLLOWING CRITERIA MUST BE MET: POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR MEETS AT LEAST TWO OF THE FOLLOWING CRITERIA: 1.) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE 2.) SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS ELEVATED AND PATIENT HAS NOT RECEIVED VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK 3.) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE 4.) RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP) (E.G., FLARED AND FRAYED METAPHYSES, OSTEOPENIA, WIDENED GROWTH PLATES, AREAS OF RADIOLUCENCY OR SCLEROSIS) 5.) PRESENCE OF TWO OR MORE OF THE FOLLOWING: RACHITIC CHEST DEFORMITY, CRANIOSYNOSTOSIS (PREMATURE CLOSURE OF SKULL BONES), DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, NEPHROCALCINOSIS, OR HISTORY OF ELEVATED SERUM CALCIUM. HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. FOR PATIENTS WITH JUVENILE-ONSET HYPOPHOSPHATASIA (HPP), ALL OF THE FOLLOWING CRITERIA MUST BE MET: POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR MEETS AT LEAST TWO OF THE FOLLOWING CRITERIA: 1.) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE 2.) SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS ELEVATED AND PATIENT HAS NOT RECEIVED VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK 3.)URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE 4.)RADIOGRAPHIC EVIDENCE OF HYPOPHOSPHATASIA (HPP) (E.G., FLARED AND FRAYED METAPHYSES, OSTEOPENIA, OSTEOMALACIA, WIDENED GROWTH PLATES, AREAS OF RADIOLUCENCY OR SCLEROSIS) 5.)PRESENCE OF TWO OR MORE OF THE FOLLOWING:RACHITIC DEFORMITIES (RACHITIC CHEST,</p>

PA Criteria	Criteria Details
	<p>BOWED LEGS, KNOCK-KNEES),PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, OR HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. STRENSIQ WILL NOT BE APPROVED FOR THE FOLLOWING PATIENTS: PATIENTS CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE [E.G., BONIVA (IBANDRONATE), FOSAMAX (ALENDRONATE), ACTONEL (RISEDRONATE)], PATIENTS WITH SERUM CALCIUM OR PHOSPHATE LEVELS BELOW THE NORMAL RANGE, PATIENTS WITH A TREATABLE FORM OF RICKETS. RENEWAL: PATIENT HAS EXPERIENCED AN IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HYPOPHOSPHATASIA (HPP) (E.G., IMPROVEMENT OF THE IRREGULARITY OF THE PROVISIONAL ZONE OF CALCIFICATION, PHYSEAL WIDENING, METAPHYSEAL FLARING, RADIOLUCENCIES, PATCHY OSTEOSCLEROSIS, RATIO OF MID-DIAPHYSEAL CORTEX TO BONE THICKNESS, GRACILE BONES, BONE FORMATION AND FRACTURES.</p>

# ASPARAGINASE

---

## Products Affected

- Oncaspar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 MONTHS
<b>Other Criteria</b>	

# ATEZOLIZUMAB

---

## Products Affected

- Tecentriq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# AVELUMAB

---

## Products Affected

- Bavencio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# AXITINIB

---

## Products Affected

- Inlyta oral tablet 1 mg, 5 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TRIAL OF AT LEAST ONE SYSTEMIC THERAPY FOR THE TREATMENT OF RCC SUCH AS NEXAVAR (SORAFENIB), TORISEL (TEMSIROLIMUS), SUTENT (SUNITINIB), VOTRIENT (PAZOPANIB), OR AVASTIN (BEVACIZUMAB) IN COMBINATION WITH INTERFERON.

# BEDAQUILINE FUMARATE

---

## Products Affected

- Sirturo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS OF AGE AND OLDER.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 WEEKS
<b>Other Criteria</b>	SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS.



# BELIMUMAB

## Products Affected

- Benlysta intravenous
- Benlysta subcutaneous

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AUTOANTIBODY POSITIVE LUPUS TEST.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: MEMBER IS CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. NO APPROVAL FOR DIAGNOSIS OF SEVERE ACTIVE LUPUS NEPHRITIS, SEVERE CENTRAL NERVOUS SYSTEM LUPUS OR CONCURRENT USE OF BIOLOGIC AGENTS OR INTRAVENOUS CYCLOPHOSPHAMIDE. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.

# BELINOSTAT

---

## Products Affected

- Beleodaq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BENDAMUSTINE

---

## Products Affected

- Bendeka

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BEVACIZUMAB

---

## Products Affected

- Avastin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BEXAROTENE

---

## Products Affected

- bexarotene
- Targretin topical

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BLINATUMOMAB

---

## Products Affected

- Blincyto intravenous kit

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: DIAGNOSIS OF PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A PATIENT WHO HAS PREVIOUSLY TRIED CHEMOTHERAPY BUT HAS RELAPSED OR IS REFRACTORY TO TREATMENT. INITIAL APPROVAL IS FOR 2 CYCLES, MAY APPROVE FOR 1 ADDITIONAL CYCLE DUE TO TREATMENT INTERRUPTION FOR DOSE MODIFICATION. RENEWAL IS APPROVED FOR PATIENTS WHO HAVE ACHIEVED COMPLETE REMISSION WITH OR WITHOUT PARTIAL HEMATOLOGICAL RECOVERY OF PERIPHERAL BLOOD COUNTS AFTER 2 CYCLES OF TREATMENT. RENEWAL IS NOT APPROVED FOR PATIENTS WHO RECEIVED AN ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANT.

# BORTEZOMIB

---

## Products Affected

- Velcade

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BOSUTINIB

---

## Products Affected

- Bosulif oral tablet 100 mg, 500 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CML: BCR-ABL MUTATIONAL ANALYSIS CONFIRMING THAT BOTH T315I AND V299L MUTATIONS ARE NOT PRESENT.



# BRIGATINIB

---

## Products Affected

- Alunbrig

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# BRODALUMAB

## Products Affected

- Siliq

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. PATIENT HAS BEEN COUNSELED ON AND EXPRESSES UNDERSTANDING OF THE RISK OF SUICIDAL IDEATION AND BEHAVIOR. RENEWAL: PATIENT HAS NOT DEVELOPED OR REPORTED WORSENING DEPRESSIVE SYMPTOMS OR SUICIDAL IDEATION AND BEHAVIORS WHILE ON TREATMENT WITH SILIQ.

# C1 ESTERASE INHIBITOR

---

## Products Affected

- Cinryze
- Haegarda

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HEMATOLOGIST, IMMUNOLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# CABOZANTINIB

---

## Products Affected

- Cometriq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# CABOZANTINIB S-MALATE - CABOMETYX

---

## Products Affected

- Cabometyx oral tablet 20 mg, 40 mg, 60 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PATIENT HAS RECEIVED PRIOR ANTIANGIOGENIC THERAPY (E.G., SUTENT [SUNITINIB], VOTRIENT [PAZOPANIB], INLYTA [AXITINIB], NEXAVAR [SORAFENIB])

# CANAKINUMAB

---

## Products Affected

- Ilaris (PF)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	CAPS: 4 YEARS AND OLDER. SJIA: 2 YEARS AND OLDER.
<b>Prescriber Restrictions</b>	PRESCRIBED OR SUPERVISED BY RHEUMATOLOGIST, DERMATOLOGIST, OR AN IMMUNOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# CANNABINOIDS

---

## Products Affected

- dronabinol

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	B VS D COVERAGE CONSIDERATION. PART D COVERAGE CONSIDERATION FOR A DIAGNOSIS OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY REQUIRES A TRIAL OF OR CONTRAINDICATION TO CONVENTIONAL ANTIEMETIC THERAPIES SUCH AS ONDANSETRON, STEROIDS INDICATED FOR EMESIS OR EMEND. NO ADDITIONAL REQUIREMENTS FOR A DIAGNOSIS OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS.

# CARFILZOMIB

---

## Products Affected

- Kyprolis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# CERITINIB

---

## Products Affected

- Zykadia

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	POSITIVE FOR ANAPLASTIC LYMPHOMA KINASE (ALK) FUSION ONCOGENE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# CERTOLIZUMAB PEGOL

## Products Affected

- Cimzia
- Cimzia Powder for Reconst

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS/ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHN'S DISEASE: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. PSA/AS: 4 MONTHS. CD: 12 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS: PREVIOUS TRIAL OF HUMIRA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA AND ONE CONVENTIONAL AGENT SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE.

# CLOBAZAM

---

## Products Affected

- Onfi oral suspension
- Onfi oral tablet 10 mg, 20 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	2 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TRIAL OF LAMOTRIGINE OR TOPIRAMATE. REQUESTS FOR ORAL SUSPENSION APPROVABLE IF PATIENT IS UNABLE TO SWALLOW OR IS UNDER THE AGE OF 5 YEARS.

# COBIMETINIB FUMARATE

---

## Products Affected

- Cotellic

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# COPANLISIB DI-HCL

---

## Products Affected

- Aliqopa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# CRIZOTINIB

---

## Products Affected

- Xalkori

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DABRAFENIB MESYLATE

---

## Products Affected

- Tafinlar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DACLATASVIR

---

## Products Affected

- Daklinza

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. NO APPROVALS FOR CONCURRENT USE WITH ANY OF THESE (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER) MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, OR RIFAMPIN. APPROVAL FOR INTERFERON INELIGIBLE PATIENTS - INTERFERON INELIGIBILITY INCLUDES CONCURRENT DIAGNOSIS OF AUTOIMMUNE HEPATITIS OR OTHER AUTOIMMUNE DISORDER, A KNOWN HYPERSENSITIVITY REACTION (SUCH AS URTICARIA, ANGIOEDEMA, BRONCHOCONSTRICTION AND ANAPHYLAXIS TO ALPHA INTERFERONS, PEG, OR ANY COMPONENT OF PEGINTERFERON), DOCUMENTED DEPRESSION, DECOMPENSATED HEPATIC DISEASE: A BASELINE NEUTROPHIL COUNT BELOW 1,500 PER MICROLITER, A BASELINE PLATELET COUNT BELOW 90,000, OR A BASELINE HEMOGLOBIN BELOW 10G/DL THAT HAS NOT RESPONDED TO TREATMENT.</p>

# DACLIZUMAB

## Products Affected

- Zinbryta

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	PRE-EXISTING HEPATIC DISEASE OR IMPAIRMENT, INCLUDING: ACTIVE HEPATITIS B AND C, AUTOIMMUNE HEPATITIS OR OTHER AUTOIMMUNE CONDITIONS INVOLVING THE LIVER, BASELINE ALT AND AST GREATER THAN OR EQUAL TO 2 TIMES UPPER LIMIT OF NORMAL (ULN).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PREVIOUS TRIAL OF TWO OF THE FOLLOWING PREFERRED AGENTS FOR MULTIPLE SCLEROSIS, SUCH AS AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR FORMULARY GLATIRAMER ACETATE. RENEWAL: REQUESTS FOR DACLIZUMAB WILL NOT BE APPROVED FOR THE FOLLOWING PATIENTS: PATIENT WITH AUTOIMMUNE HEPATITIS OR HEPATIC INJURY.

# DALFAMPRIDINE

---

## Products Affected

- Ampyra

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NEUROLOGIST
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT IN WALKING ABILITY.

# DARATUMUMAB

---

## Products Affected

- Darzalex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DASATINIB

---

## Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PREVIOUSLY-TREATED CHRONIC MYELOID LEUKEMIA (CML) REQUIRES BCR-ABL MUTATIONAL ANALYSIS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, V299L, T315A, F317L/V/I/C.

# DEFERASIROX

## Products Affected

- Exjade
- Jadenu
- Jadenu Sprinkle

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST
Coverage Duration	INITIAL: 6 MONTHS RENEWAL: 12 MONTHS
Other Criteria	CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS INITIAL: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L. RENEWAL: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L. NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) INITIAL: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L AND LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G DRY WEIGHT OR GREATER. RENEWAL: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE THAN 300 MCG/L AND LIC OF 3 MG FE/G DRY WEIGHT OR GREATER

# DEFERIPRONE

## Products Affected

- Ferriprox

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST
Coverage Duration	INITIAL: 6 MONTHS RENEWAL: 12 MONTHS
Other Criteria	INITIAL CRITERIA: REQUIRES TRIAL OF EXJADE, JADENU, OR GENERIC DEFEROXAMINE AND ONE OF THE FOLLOWING CRITERIA 1) PHYSICIAN ATTESTATION THAT PATIENT IS EXPERIENCING INTOLERABLE TOXICITIES, CLINICALLY SIGNIFICANT ADVERSE EFFECTS, OR CONTRAINDICATION TO THESE THERAPIES OR 2) INADEQUATE CHELATION DEFINED BY ONE OF THE FOLLOWING: A) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 2500 MCG/L OR B) EVIDENCE OF CARDIAC IRON ACCUMULATION. RENEWAL: SERUM FERRITIN LEVELS MUST BE CONSISTENTLY ABOVE 500MCG/L

# DEFEROXAMINE

---

## Products Affected

- deferoxamine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	AT LEAST 3 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST
<b>Coverage Duration</b>	INITIAL: 6 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000MCG/L RENEWAL: SERUM FERRITIN LEVELS MUST BE CONSISTENTLY ABOVE 500MCG/L



# DEFLAZACORT

---

## Products Affected

- Emflaza oral suspension mg
- Emflaza oral tablet 18 mg, 30 mg, 36 mg, 6

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	REPORTED INTOLERANCE TO PREDNISONE OR PREDNISOLONE IS A REPORTED INTOLERANCE IN THE EMFLAZA PRESCRIBING INFORMATION AS AN ADVERSE EVENT OF EMFLAZA
<b>Required Medical Information</b>	PHYSICIAN ATTESTATION OF GENETIC TESTING CONFIRMING DMD DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST SPECIALIZING IN THE TREATMENT OF DMD.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL CRITERIA: REQUIRE TRIAL OF PREDNISONE OR PREDNISOLONE FOR AT LEAST 6 MONTHS. REQUEST DUE TO LACK OF EFFICACY OF PREDNISONE OR PREDNISOLONE AND ALL OF THE FOLLOWING CRITERIA ARE MET: 1)PATIENT IS NOT IN STAGE 1 (PRE-SYMPTOMATIC PHASE) 2) STEROID MYOPATHY HAS BEEN RULED OUT 3) PHYSICIAN ATTESTATION OF DETERIORATION IN AMBULATION, FUNCTIONAL STATUS, OR PULMONARY FUNCTION CONSISTENT WITH ADVANCING DISEASE USING STANDARD MEASURES [SUCH AS 6-MINUTE WALK DISTANCE (6MWD), TIME TO ASCEND/DESCEND 4 STAIRS, RISE FROM FLOOR TIME (GOWER'S MANEUVER), 10-METER RUN/WALK TIME, OR NORTH STAR AMBULATORY ASSESSMENT (NSAA), PHYSICIAN GLOBAL ASSESSMENTS (PGA), PULMONARY FUNCTION (FVC, PFTS), UPPER LIMB STRENGTH (PROPELLING A WHEELCHAIR 30 FEET)]. REQUEST DUE TO ADVERSE EFFECTS OF PREDNISONE OR PREDNISOLONE THAT ARE NOT LISTED IN THE PRESCRIBING INFORMATION OF EMFLAZA REQUIRE PHYSICIAN ATTESTATION OF LITERATURE SUPPORTING EMFLAZA MITIGATES NAMED ADVERSE CONSEQUENCE.</p> <p>RENEWAL: APPROVAL FOR PATIENTS CURRENTLY AMBULATORY REQUIRES PHYSICIAN ATTESTATION OF FUNCTION, STABILIZATION, OR IMPROVEMENT IN STANDARD MEASURES SINCE TREATMENT WITH EMFLAZA THAT ARE BEING MONITORED, TRACKED, AND DOCUMENTED CONSISTENTLY. APPROVAL FOR PATIENTS CURRENTLY NON-AMBULATORY REQUIRES PHYSICIAN ATTESTATION OF MAINTENANCE OR LESS THAN EXPECTED DECLINE IN PULMONARY FUNCTION AND/OR UPPER LIMB STRENGTH ASSESSED BY STANDARD MEASURES (SUCH AS PULMONARY FUNCTION [FVC, PFTS], UPPER LIMB STRENGTH MEASURES [PROPELLING A WHEELCHAIR 30 FEET], PHYSICIAN GLOBAL ASSESSMENTS [PGA]) SINCE TREATMENT WITH EMFLAZA THAT ARE BEING MONITORED, TRACKED, AND DOCUMENTED CONSISTENTLY.</p>

# DELAFLOXACIN

---

## Products Affected

- Baxdela oral

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ANIMAL OR HUMAN BITE, NECROTIZING FASCIITIS, DIABETIC FOOT INFECTION, DECUBITIS ULCER FORMATION, MYONECROSIS OR ECTHYMA GANGRENOSUM
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ONE MONTH
<b>Other Criteria</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST OR ABSSSI ORGANISM ANTIMICROBIAL SUSCEPTIBILITY TESTING SHOWS SUSCEPTIBILITY TO DELAFLOXACIN AND RESISTANCE TO ONE PREFERRED FORMULARY STANDARD OF CARE AGENT OR IF SENSITIVITY RESULTS ARE UNAVAILABLE: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED FORMULARY AGENTS: A PENICILLIN, A FLUOROQUINOLONE, A CEPHALOSPORIN, OR A GRAM POSITIVE TARGETING ANTIBIOTIC

# DESIRUDIN

---

## Products Affected

- Iprivask

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 MONTH
<b>Other Criteria</b>	

# DEUTETRABENAZINE

---

## Products Affected

- Austedo oral tablet 12 mg, 6 mg, 9 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DICHLORPHENAMIDE

---

## Products Affected

- Keveyis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	HEPATIC INSUFFICIENCY, PULMONARY OBSTRUCTION, OR A HEALTH CONDITION THAT WARRANTS CONCURRENT USE OF HIGH-DOSE ASPIRIN
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS AND OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 2 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	RENEWAL REQUIRES THE PATIENT EXPERIENCED AT LEAST TWO FEWER ATTACKS PER WEEK FROM THEIR BASELINE

# DICLOFENAC EPOLAMINE

---

## Products Affected

- Flector

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# DICLOFENAC TOPICAL

---

## Products Affected

- diclofenac sodium topical gel 3 %

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# DIMETHYL FUMARATE

---

## Products Affected

- Tecfidera oral capsule, delayed release(DR/EC) 120 mg, 120 mg (14)- 240 mg (46), 240 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DINUTUXIMAB

---

## Products Affected

- Unituxin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# DROXIDOPA

## Products Affected

- Northera

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE (LYING FACE UP) POSITION AT BASELINE AND RENEWAL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: DIAGNOSIS OF ORTHOSTATIC HYPOTENSION AS DOCUMENTED BY A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION. RENEWAL: PATIENT HAD AN INCREASE IN SYSTOLIC BLOOD PRESSURE FROM BASELINE OF AT LEAST 10 MMHG UPON STANDING FROM A SUPINE (LYING FACE UP) POSITION.

# DUPILUMAB

## Products Affected

- Dupixent

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PATIENT HAS MINIMUM BODY SURFACE AREA (BSA) INVOLVEMENT OF AT LEAST 10%, ECZEMA AREA AND SEVERITY INDEX (EASI) SCORE OF AT LEAST 16, OR PHYSICIAN GLOBAL ASSESSMENT (PGA) SCORE OF AT LEAST 3. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL:12 MONTHS
<b>Other Criteria</b>	INITIAL: PREVIOUS TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING: TOPICAL CORTICOSTEROIDS, TOPICAL CALCINEURIN INHIBITORS [E.G., ELIDEL (PIMECROLIMUS), GENERIC TACROLIMUS OINTMENT], OR TOPICAL PDE4 INHIBITOR [E.G., EUCRISA (CRISABOROLE)].

# DURVALUMAB

---

## Products Affected

- Imfinzi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# EDARAVONE

---

## Products Affected

- Radicava

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ELBASVIR/GRAZOPREVIR

## Products Affected

- Zepatier

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD PUGH B OR C)
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS. FOR GENOTYPE 1A -TESTING FOR NS5A RESISTANCE-ASSOCIATED POLYMORPHISMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. NO CONCURRENT USE OF SOVALDI AND ANY OF THE FOLLOWING AGENTS: PHENYTOIN, CARBAMAZEPINE, RIFAMPIN, EFAVIRENZ, ATAZANAVIR, DARUNAVIR, LOPINAVIR, SAQUINAVIR, TIPRANAVIR, CYCLOSPORINE, NAFCILLIN, KETOCONAZOLE, MODAFINIL, BOSENTAN, ETRAVIRINE, ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR, ATORVASTATIN AT DOSES GREATER THAN 20MG PER DAY OR ROSUVASTATIN AT DOSES GREATER THAN 10MG PER DAY.</p>



# ELIGLUSTAT TARTRATE

---

## Products Affected

- Cerdelga

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ELOSULFASE ALFA

---

## Products Affected

- Vimizim

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME OF MEMBERSHIP IN PLAN.
<b>Other Criteria</b>	

# ELOTUZUMAB

---

## Products Affected

- Empliciti

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ELTROMBOPAG

## Products Affected

- Promacta

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ITP:INITIAL: 2MO.RENEW:AFTER RESPONSE:12MO, INADEQUATE DOSE:2MO.HCV:12MO.SEVERE APLASTIC ANEMIA:12MO
Other Criteria	CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA PURPURA (ITP): INITIAL: TRIAL OF OR CONTRAINDICATION TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY. ITP: RENEWAL: PATIENT HAS A CLINICAL RESPONSE AS DEFINED BY AN INCREASE IN PLATELET COUNT OF GREATER THAN OR EQUAL TO 50 X10 <sup>9</sup> /L (GREATER THAN OR EQUAL TO 50,000 PER UL) AT THE MAX DOSE OF 75MG PER DAY FOR 4 WEEKS. HEPATITIS C: CONCURRENT INTERFERON THERAPY.

# ENASIDENIB

---

## Products Affected

- Idhifa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ENDOTHELIN RECEPTOR ANTAGONISTS

## Products Affected

- Letairis
- Opsumit
- Tracleer

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. LETAIRIS: PATIENT DOES NOT HAVE IDIOPATHIC PULMONARY FIBROSIS (IPF) TRACLEER: PATIENT DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASES IN BILIRUBIN BY 2 OR MORE TIMES ULN. PATIENT IS NOT CONCURRENTLY TAKING CYCLOSPORINE A OR GLYBURIDE. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS.

# ENZALUTAMIDE

---

## Products Affected

- Xtandi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TRIAL OF OR CONTRAINDICATION TO ZYTIGA (ABIRATERONE ACETATE) IS ALSO REQUIRED IN PATIENTS WHO DO NOT HAVE A CONTRAINDICATION OR INTOLERANCE TO PREDNISONE.

# EPOPROSTENOL IV

## Products Affected

- epoprostenol (glycine)

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	COVERED UNDER LOCAL COVERAGE POLICY OF APPLICABLE MEDICARE DMERC.
<b>Required Medical Information</b>	FORMULARY DRUG ADMINISTERED IN A LONG TERM CARE FACILITY TO A PATIENT WHOSE PART A COVERAGE HAS EXPIRED OR FORMULARY DRUG NOT ADMINISTERED VIA AN IMPLANTABLE PUMP OR AN EXTERNAL PUMP OR DRUG ADMINISTERED VIA AN IMPLANTABLE PUMP/AN EXTERNAL PUMP. DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS III-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT HAS SHOWN IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.



# ERLOTINIB

---

## Products Affected

- Tarceva oral tablet 100 mg, 150 mg, 25 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# ERYTHROPOIESIS STIMULATING AGENTS - EPOETIN ALFA

---

## Products Affected

- EPOGEN 10,000 UNITS/ML VIAL SDV, P/F, OUTER
- Epogen injection solution 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL
- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/2 mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL OFF LABEL ANEMIA IN HEPATITIS C BEING TREATED IN COMBINATION WITH RIBAVIRIN AND INTERFERON ALFA OR PEGINTERFERON ALFA.
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>INITIAL: CHRONIC RENAL FAILURE (CRF) AND ANEMIA RELATED TO ZIDOVUDINE THERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10G/DL. CANCER CHEMOTHERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10G/DL ANEMIA DUE TO CONCURRENT HEPATITIS C TREATMENT WITH RIBAVIRIN PLUS INTERFERON ALFA/PEGINTERFERON ALFA REQUIRES A HEMOGLOBIN LEVEL LESS THAN 10G/DL AND RIBAVIRIN DOSE REDUCTION (UNLESS CONTRAINDICATED).ELECTIVE NON-CARDIAC OR NON-VASCULAR SURGERY REQUIRES A HEMOGLOBIN LEVEL LESS THAN 13G/DL. RENEWAL: CHRONIC RENAL FAILURE REQUIRES THAT THE PATIENT MEETS ONE OF THE FOLLOWING: IF THE PATIENT IS CURRENTLY RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 11G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 11G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. IF THE PATIENT IS NOT RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 10G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 10G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. ANEMIA DUE TO CONCURRENT HEPATITIS C TREATMENT WITH RIBAVIRIN PLUS INTERFERON ALFA/PEGINTERFERON ALFA, OR ANEMIA DUE TO ZIDOVUDINE THERAPY REQUIRES HEMOGLOBIN LEVELS BETWEEN 10G/DL AND 12G/DL. ANEMIA DUE TO EFFECT OF CONCOMITANTLY ADMINISTERED CANCER CHEMOTHERAPY REQUIRES A HEMOGLOBIN LEVEL OF LESS THAN 10 G/DL OR THAT THE HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<p>ANEMIA FROM MYELOSUPPRESSIVE CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE:12 MONTHS.SURGERY:1 MO.HCV:6 MOS.</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	ALL INDICATIONS: TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.

# ERYTHROPOIESIS STIMULATING AGENTS - MIRCERA

## Products Affected

- Mircera injection syringe 100 mcg/0.3 mL, 200 mcg/0.3 mL, 50 mcg/0.3 mL, 75 mcg/0.3 mL

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC RENAL FAILURE REQUIRES HEMOGLOBIN LEVELS LESS THAN 10G/DL RENEWAL: CHRONIC RENAL FAILURE REQUIRES THAT THE PATIENT MEETS ONE OF THE FOLLOWING: IF THE PATIENT IS CURRENTLY RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 11G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 11G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. IF THE PATIENT IS NOT RECEIVING DIALYSIS TREATMENT: 1) HEMOGLOBIN LEVEL OF LESS THAN 10G/DL OR 2) HEMOGLOBIN LEVEL THAT HAS REACHED 10G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ANEMIA DUE TO CKD WITH OR WITHOUT DIALYSIS: 12 MONTHS.
Other Criteria	TRIAL OF PROCRIT. PART D MEMBER RECEIVING DIALYSIS OR IDENTIFIED AS A PART D END STAGE RENAL DISEASE MEMBER: PAYS UNDER PART B.

# ETANERCEPT

## Products Affected

- Enbrel
- Enbrel SureClick

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING AT LEAST 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS: 18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PLAQUE PSORIASIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA: 6 MONTHS. PJIA: 3 MONTHS. PSA/AS/PSO: 4 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA.</p>

# ETEPLIRSEN

## Products Affected

- Exondys 51

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PHYSICIAN ATTESTATION OF GENETIC TESTING CONFIRMING THAT MUTATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) GENE IS AMENABLE TO EXON 51 SKIPPING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 24 WEEKS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL CRITERIA: PATIENT IS AMBULATORY AND IS CURRENTLY RECEIVING TREATMENT WITH OR HAS A CONTRAINDICATION TO CORTICOSTEROIDS. RENEWAL CRITERIA: PATIENT HAS MAINTAINED OR DEMONSTRATED A LESS THAN EXPECTED DECLINE IN AMBULATORY ABILITY IN MUSCLE FUNCTION ASSESSMENTS OR OTHER MUSCLE FUNCTION (I.E. PULMONARY OR CARDIAC FUNCTION) DURING THE PAST 24 WEEKS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.



# EVEROLIMUS

---

## Products Affected

- Afinitor Disperz 7.5 mg
- Afinitor oral tablet 10 mg, 2.5 mg, 5 mg,

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED RENAL CELL CARCINOMA (RCC): TRIAL OF OR CONTRAINDICATION TO SUTENT OR NEXAVAR.

# EVOLOCUMAB

---

## Products Affected

- Repatha Pushtronex
- Repatha SureClick
- Repatha Syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	HEFH OR ASCVD: 18 YEARS OF AGE AND OLDER.
Prescriber Restrictions	CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
Coverage Duration	INITIAL: 6 MONTHS RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): MUST HAVE LDL LEVEL GREATER THAN 100MG/DL ON MAXIMAL DRUG TREATMENT (MDT) FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS AND ONE OF THE FOLLOWING: (1) HEFH DETERMINED BY SIMON BROOME DIAGNOSTIC (SBD) CRITERIA OR A SCORE OF 6 OR GREATER ON THE DUTCH LIPID NETWORK (DLN) CRITERIA OR (2) ASCVD AS SUBSTANTIATED BY PHYSICIAN ATTESTATION.</p> <p>HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): LDL LEVEL GREATER THAN 100MG/DL ON MDT FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS AND HOFH DETERMINED BY ONE OF THE FOLLOWING: 1) SBD CRITERIA, 2) A SCORE OF 8 OR GREATER ON THE DLN CRITERIA, OR 3) A CLINICAL DIAGNOSIS BASED ON A HISTORY OF AN UNTREATED LDL-C CONCENTRATION GREATER THAN 500 MG/DL TOGETHER WITH EITHER XANTHOMA BEFORE 10 YEARS OF AGE, OR EVIDENCE OF HEFH IN BOTH PARENTS. NO CONCURRENT USE OF OTHER PCSK9 INHIBITORS. INITIAL THERAPY: FOR STATIN TOLERANT PATIENTS: MUST HAVE TRIED MAXIMALLY TOLERATED DOSE OF HIGH INTENSITY STATIN SUCH AS ATORVASTATIN OR ROSUVASTATIN. FOR STATIN INTOLERANT PATIENTS WITH HEFH OR ASCVD: ONE OF THE FOLLOWING MUST BE MET: PHYSICIAN ATTESTATION OF STATIN INTOLERANCE (INCLUDING BUT NOT LIMITED TO MYOPATHY), OR PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AT ANY DOSE. PATIENTS WITH CONTRAINDICATIONS TO STATINS INCLUDING ACTIVE DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT OR HYPERSENSITIVITY REACTIONS WILL BE APPROVED FOR REPATHA THERAPY WITHOUT DOCUMENTED STATIN INTOLERANCE. FOR STATIN INTOLERANT PATIENTS WITH HOFH: MUST BE ON MAX LIPID-LOWERING THERAPY INCLUDING ONE OF THE FOLLOWING: NIACIN, BILE ACID SEQUESTRANT, LOMITAPIDE OR MIPOMERSEN. QUALIFIERS MUST PROVIDE DOCUMENTATION OF STATIN INTOLERANCE TO ONE OF THE FOLLOWING: A HIGH INTENSITY STATIN (ROSUVASTATIN OR ATORVASTATIN) OR OTHER STATIN THERAPY AT ANY DOSE. STATIN INTOLERANT PATIENTS</p>

PA Criteria	Criteria Details
	<p>MUST BE ON MAXIMAL LIPID-LOWERING MEDICATION (NON-STATIN THERAPY) FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS WITH DOCUMENTATION OF STATIN INTOLERANCE TO ATORVASTATIN OR ROSUVASTATIN OR STATIN THERAPY AT ANY DOSE. DOCUMENTATION OF STATIN INTOLERANCE INCLUDES: (1) PHYSICIAN ATTESTATION, OR (2) PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AND HAS EXPERIENCED SKELETAL MUSCLE RELATED EVENTS (E.G. MYOPATHY). RENEWAL CRITERIA: RECEIVING PRIOR REPATHA THERAPY FOR AT LEAST 6 MONTHS AND NOT ON CONCURRENT THERAPY WITH OTHER PCSK9 INHIBITORS, MIPOMERSEN, OR LOMITAPIDE.</p>

# FENTANYL NASAL SPRAY

## Products Affected

- Lazanda

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	<p>CANCER: CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION (SUCH AS MORPHINE SULFATE ER, OXYCODONE ER, OR FENTANYL). EITHER A TRIAL OR CONTRAINDICATION TO AT LEAST ONE (1) IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT (SUCH AS MORPHINE SULFATE IR, OXYCODONE/ASPIRIN, OXYCODONE/ACETAMINOPHEN, CODEINE/ACETAMINOPHEN, HYDROMORPHONE, OR MEPERIDINE) OR MEMBER HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES AND TRIAL OR CONTRAINDICATION TO GENERIC FENTANYL CITRATE LOZENGE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.</p>

# FENTANYL TRANSMUCOSAL AGENTS - FENTANYL CITRATE

## Products Affected

- fentanyl citrate

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	CANCER: CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION (SUCH AS MORPHINE SULFATE ER, OXYCODONE ER, OR FENTANYL). EITHER A TRIAL OR CONTRAINDICATION TO AT LEAST ONE (1) IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT (SUCH AS MORPHINE SULFATE IR, OXYCODONE/ASPIRIN, OXYCODONE/ACETAMINOPHEN, CODEINE/ACETAMINOPHEN, HYDROMORPHONE, OR MEPERIDINE) OR MEMBER HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# FINGOLIMOD

---

## Products Affected

- Gilenya

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# FOLIC ACID OTC

---

## Products Affected

- FOLIC ACID 400 MCG TABLET  
S/F,P/F,LACTOSE-FREE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	N/A
<b>Other Criteria</b>	RESTRICTED TO FEMALES, AGES 14 THROUGH 45 YEARS, TO PREVENT NEURAL TUBE DEFECTS IN CURRENT AND FUTURE PREGNANCIES ONLY.



# GEFITINIB

---

## Products Affected

- Iressa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# GEMTUZUMAB OZOGAMICIN

---

## Products Affected

- Mylotarg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# GLATIRAMER ACETATE

---

## Products Affected

- Copaxone subcutaneous syringe 40 mg/mL
- Glatopa mg/mL, 40 mg/mL
- glatiramer subcutaneous syringe 20

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# GLECAPREVIR/PIBRENTASVIR

## Products Affected

- Mavyret

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.
<b>Exclusion Criteria</b>	MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C)
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED OR CONTRAINDICATED BY THE MANUFACTURER: CARBAMAZEPINE, RIFAMPIN, ETHINYL ESTRADIOL-CONTAINING MEDICATION, ATAZANAVIR, DARUNAVIR, LOPINAVIR, RITONAVIR, EFAVIRENZ, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, OR CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY. PATIENT MUST NOT HAVE PRIOR FAILURE OF A DAA REGIMEN WITH NS5A INHIBITOR AND HCV PROTEASE INHIBITOR.</p>

# GLUCOSE TEST STRIPS AND LANCETS

---

## Products Affected

- 1ST TIER COMFORTOUCH 28G LANCET
- 1ST TIER COMFORTOUCH 30G LANCET
- ACCU-CHEK AVIVA PLUS TEST STRP
- ACCU-CHEK COMPACT PLUS STRIPS 3 TEST DRUMS
- ACCU-CHEK COMPACT STRIPS MEDICARE-M-CAID ONLY
- ACCU-CHEK FASTCLIX LANCETS
- ACCU-CHEK GUIDE TEST STRIP
- ACCU-CHEK MULTICLIX LANCETS
- ACCU-CHEK SAFE-T-PRO 23G LANCET
- ACCU-CHEK SAFE-T-PRO PLUS 23G
- ACCU-CHEK SMARTVIEW TEST STRIP
- ACCU-CHEK SOFTCLIX LANCETS
- ACCUTREND GLUCOSE TEST STRIP
- ACTI-LANCE LITE 28G LANCETS
- ACTI-LANCE SPECIAL 17G LANCETS
- ACTI-LANCE UNIVERS 23G LANCETS
- ADVANCED TRAVEL 28G LANCETS 28G,SINGLE-USE,STRL
- ADVANCED TRAVEL 30G LANCETS
- ADVOCATE 26G LANCETS 26 G,STERILE
- ADVOCATE 26G LANCETS STERILE
- ADVOCATE 30G LANCETS TWIST TOP
- ADVOCATE REDI-CODE TEST STRIP
- ADVOCATE REDI-CODE+ TEST STRIP NO CODING
- ADVOCATE TEST STRIP
- AGAMATRIX AMP TEST STRIPS
- ALTERNATE SITE 26G LANCETS RECAPABLE
- ASSURE 4 TEST STRIPS
- ASSURE COMFORT 30G LANCETS
- ASSURE HAEMOLANCE PLUS 18G
- ASSURE HAEMOLANCE PLUS 21G
- ASSURE HAEMOLANCE PLUS 25G
- ASSURE HAEMOLANCE PLUS 28G
- ASSURE LANCE 25G LANCETS
- ASSURE LANCE 28G LANCETS
- ASSURE LANCE PLUS 21G LANCETS
- ASSURE LANCE PLUS 25G LANCETS
- ASSURE LANCE PLUS 30G LANCETS
- ASSURE PLATINUM TEST STRIPS
- ASSURE PRISM MULTI TEST STRIPS
- BD MICROTAINER 21G LANCETS
- BD MICROTAINER 30G LANCETS
- BD ULTRA-FINE 33G LANCETS
- BD ULTRA-FINE II 30G LANCETS
- BLOOD GLUCOSE TEST STRIP NO CODING
- BLOOD GLUCOSE TEST STRIPS
- BLOOD LANCETS 30G EASY TWIST
- BULLSEYE MINI SAFETY 21G
- BULLSEYE MINI SAFETY 25G LANCET
- CAREONE ULTRA THIN LANCET
- CARESENS N TEST STRIPS NO CODING
- CARESENS ULTRA THIN 30G LANCET
- CARETOUCH TWIST 28G LANCET
- CARETOUCH TWIST 30G LANCET
- CHOICEDM CLARUS TEST STRIPS
- CLEVER CHEK ULTRA THIN 30G
- CLEVER CHOICE MICRO TEST STRIP
- CLEVER CHOICE PRO TEST STRIP
- CLEVER CHOICE TALK TEST STRIPS
- CLEVER CHOICE TEST STRIPS AUTO-CODE
- CLEVER CHOICE VOICE+ TST STRIP AUTO-CODE

- COAGUCHEK LANCETS
- COMFORT EZ SAFETY 21G LANCETS
- COMFORT EZ SAFETY 23G LANCETS
- COMFORT EZ SAFETY 28G LANCETS
- COMFORT LANCETS
- CONTOUR NEXT STRIPS
- CONTOUR TEST STRIPS
- COOL GLUCOSE TEST STRIP
- CVS ADVANCED GLUCOSE TEST STR
- CVS THIN 26G LANCETS
- CVS ULTRA THIN 30G LANCETS
- DARIO BLOOD GLUCOSE TEST STRIP
- DIATRUE PLUS TEST STRIP
- DROPLET 30G LANCETS
- E-Z JECT LANCETS
- E-ZJECT COLOR 32G LANCETS
- E-ZJECT COLOR 33G LANCETS
- E-ZJECT SUPER THIN 30G LANCETS SUPER THIN
- E-ZJECT THIN LANCETS 26 GAUGE
- EASY COMFORT 30G LANCETS 30G,TWIST TOP,STRL
- EASY GLUCO G2 TEST STRIP
- EASY PLUS GLUCOSE TEST STRIP
- EASY PLUS II TEST STRIPS
- EASY STEP GLUCOSE TEST STRIPS
- EASY TALK GLUCOSE TEST STRIP
- EASY TOUCH 28G LANCETS 28G,PULL TOP,STERILE
- EASY TOUCH GLUCOSE TEST STRIP
- EASY TOUCH SAFETY 21G LANCETS
- EASY TOUCH SAFETY 23G LANCETS
- EASY TOUCH SAFETY 26G LANCETS
- EASY TOUCH TWIST 28G LANCETS
- EASY TOUCH TWIST 30G LANCETS
- EASY TOUCH TWIST 32G LANCETS
- EASY TOUCH TWIST 33G LANCETS
- EASY TRAK GLUCOSE TEST STRIP
- EASY TWIST & CAP 28G LANCETS
- EASYGLUCO PLUS TEST STRIPS
- EASYGLUCO TEST STRIPS
- EASYMAX 15 GLUCOSE TEST STRIP
- EASYMAX GLUCOSE TEST STRIPS MEDICAL BENEFIT USE
- ELEMENT COMPACT TEST STRIPS
- ELEMENT TEST STRIPS
- EMBRACE 30G LANCETS
- EMBRACE EVO TEST STRIPS
- EMBRACE PRO TEST STRIPS
- EMBRACE TEST STRIPS
- EVENCARE G2 TEST STRIP
- EVENCARE G3 TEST STRIP
- EVENCARE GLUCOSE TST STRIPS
- EVENCARE MINI GLUCOSE TEST STR
- EVOLUTION TEST STRIPS
- EZ SMART 28G LANCETS
- EZ SMART PLUS TEST STRIPS
- EZ SMART TEST STRIPS
- FIFTY50 GLUCOSE TEST STRIP
- FIFTY50 SAFETY SEAL 30G LANCET
- FIFTY50 SAFETY SEAL 32G LANCET
- FINE 30 UNIVERSAL 30G LANCETS
- FINGERSTIX LANCETS
- FORA 30G LANCETS TWIST OFF,SINGLE USE
- FORA BLOOD GLUCOSE TEST STRIP
- FORA D15G GLUCOSE TEST STRIPS
- FORA D20 GLUCOSE TEST STRIPS
- FORA D40-G31 TEST STRIPS
- FORA G20 GLUCOSE TEST STRIPS
- FORA G30A GLUCOSE TEST STRIP
- FORA GD50 TEST STRIPS
- FORA TN'G VOICE TEST STRIPS
- FORA V10 GLUCOSE TEST STRIP
- FORA V10-V12-D10-D20 STRIPS
- FORA V12 GLUCOSE TEST STRIP
- FORA V20 GLUCOSE TEST STRIPS
- FORA V30A GLUCOSE TEST STRIP
- FORACARE 30G LANCETS
- FORACARE GD20 TEST STRIPS
- FORACARE GD40 GLUCOSE STRIPS

- FORTISCARE GLUCOSE TEST STRIPS
- FREESTYLE 28G LANCETS
- FREESTYLE INSULINX TEST STRIP NO CODE
- FREESTYLE INSULINX TEST STRIPS
- FREESTYLE LITE TEST STRIP
- FREESTYLE LITE TEST STRIPS
- FREESTYLE PREC NEO TEST STRIPS
- FREESTYLE TEST STRIPS
- FREESTYLE UNISTIK 2 LANCETS
- GE100 BLOOD GLUCOSE TEST STRIP 2 VIALS X 25 STRIPS
- GENSTRIP GLUCOSE TEST STRIP
- GENUITIMATE TEST STRIP
- GLUCO NAVII GLUCOSE TEST STRIP
- GLUCOCARD 01 SENSOR PLUS STRIP
- GLUCOCARD EXPRESSION TEST STRP
- GLUCOCARD SHINE TEST STRIPS
- GLUCOCARD VITAL SENSOR STRIP
- GLUCOCARD VITAL TEST STRIPS
- GLUCOCOM 28G LANCETS
- GLUCOCOM 30G LANCETS
- GLUCOCOM 33G LANCETS
- GLUCOCOM GLUCOSE TEST STRIP
- GMATE 30G LANCETS
- GMATE TEST STRIPS
- GNP UNIVERSAL 1 STANDARD 21G
- GNP UNIVERSAL 1 SUPER THIN 30G
- GS BLOOD GLUCOSE TEST STRIP PREMIUM, NO CODE
- HEALTHPRO GLUCOSE TEST STRIPS
- HEALTHY ACCENTS UNILET 30G
- INCONTROL SUPER THIN 30G LANCT
- INCONTROL ULTRA THIN 28G LANCT
- INFINITY TEST STRIPS
- INJECT EASE 28G LANCETS
- INJECT EASE 30G LANCETS
- INVACARE 30G LANCETS
- KRO PREMIUM BLOOD GLUCOSE TEST NO CODING, PREMIUM
- KRO UNIVERSAL 1 THIN 26G LANCT
- KROGER SUPER THIN LANCETS
- LANCETS 33G
- LANCETS THIN 23G
- LANCETS ULTRA THIN 26G
- LIBERTY TEST STRIPS BLOOD GLUCOSE
- LITE TOUCH 30G LANCETS
- LITE TOUCH 33G LANCETS
- LONGS THIN LANCETS 26G 26G
- MEDLANCE PLUS 21G LANCETS UNIVERSAL
- MEDLANCE PLUS 30G LANCETS SUPERLITE, 1.2MM
- MEDLANCE PLUS LITE 25G LANCETS STERILE
- MICRO THIN 33G LANCETS UNIVERSAL 1
- MICRODOT TEST STRIPS
- MICRODOT XTRA TEST STRIPS
- MICROLET LANCETS
- MONOLET 21G LANCETS
- MONOLET THIN 28G LANCETS
- MYGLUCOHEALTH 30G LANCETS
- MYGLUCOHEALTH TEST STRIPS
- NEUTEK 2TEK TEST STRIPS
- NOVA MAX GLUCOSE TEST STRIP
- NOVA SAFETY 23G LANCETS
- NOVA SAFETY 28G LANCETS
- NOVA SUREFLEX THIN LANCETS
- ON CALL 30G LANCET
- ON CALL EXPRESS TEST STRIP
- ON CALL PLUS 30G LANCET
- ON CALL PLUS TEST STRIP
- ON CALL VIVID TEST STRIP
- ON-THE-GO 30G LANCETS GENTLE, 1.5MM
- ONE TOUCH DELICA 33G LANCETS
- ONETOUCH DELICA 30G LANCETS
- ONETOUCH DELICA 33G LANCETS
- ONETOUCH SURESOFT LANCING DEV DEVICE & 18G LANCETS



- ONETOUCH ULTRA TEST STRIPS
- ONETOUCH ULTRASOFT LANCETS
- ONETOUCH VERIO TEST STRIP
- OPTIUM EZ TEST STRIP
- OPTIUM TEST STRIP
- OPTUMRX TEST STRIP
- PHARMACIST CHOICE 30G LANCETS ULTRA THIN
- PHARMACIST CHOICE TEST STRIPS
- PRECISION PCX PLUS TEST STR
- PRECISION PCX TEST STRIPS
- PRECISION POINT OF CARE STR
- PRECISION Q-I-D TEST STRIPS
- PRECISION XTRA TEST STRIPS
- PREMIUM V10 GLUCOSE TEST STRIP
- PRESSURE ACTIVATED 21G LANCETS
- PRESSURE ACTIVATED 28G LANCETS
- PRO COMFORT 30G LANCETS
- PRO COMFORT 31G LANCET
- PRODIGY NO CODING TEST STRIPS
- PRODIGY PRESSURE ACTIVATED 28G
- PRODIGY SAFETY 26G LANCETS
- PRODIGY TWIST TOP 28G LANCET
- PUSH BUTTON SAFETY 21G LANCET
- PUSH BUTTON SAFETY 28G LANCET
- QUINTET AC GLUCOSE TEST STRIPS
- QUINTET GLUCOSE TEST STRIPS
- RA E-ZJECT 26G LANCETS
- RA E-ZJECT 28G LANCETS
- READYLANCE 21G SAFETY LANCETS
- READYLANCE 23G SAFETY LANCETS
- READYLANCE 26G SAFETY LANCETS
- READYLANCE 28G SAFETY LANCETS
- READYLANCE 30G SAFETY LANCETS
- REFUAH PLUS TEST STRIPS
- RELIAMED 30G LANCETS
- RELIAMED SAFETY 23G LANCETS
- RELIAMED SAFETY 28G LANCETS LATEX-FREE
- RELIAMED SAFETY SEAL 28G LANCET
- RELIAMED SAFETY SEAL 30G LANCET
- RELION CONFIRM-MICRO TEST STRP
- RELION MICRO TEST STRIPS
- RELION PRIME TEST STRIPS
- RELION THIN 26G LANCETS
- RELION ULTIMA TEST STRIPS
- RELION ULTRA THIN PLUS 33G
- RELION ULTRA THIN PLUS LANCETS
- REVEAL TEST STRIP
- RIGHTEST GL300 30G LANCETS
- RIGHTEST GS100 TEST STRIPS
- RIGHTEST GS250S TEST STRIPS
- RIGHTEST GS260 TEST STRIPS
- RIGHTEST GS300 TEST STRIPS
- RIGHTEST GS550 TEST STRIPS
- SAFETY 21G LANCETS LATEX-FREE
- SAFETY 28G LANCETS LATEX-FREE
- SAFETY LANCETS 26G
- SAFETY SEAL 28G LANCETS
- SAFETY SEAL 30G LANCETS
- SAFETY-LET 30G LANCETS
- SINGLE-LET LANCETS
- SM COLOR LANCETS 21G
- SM LANCETS 21G
- SM THIN LANCETS 26G
- SMART SENSE COLOR 33G LANCETS
- SMART SENSE STANDARD 21G
- SMART SENSE TEST STRIPS PREMIUM, NO CODE
- SMART SENSE THIN 26G LANCETS
- SMARTEST LANCET
- SMARTEST TEST STRIPS
- SOFT TOUCH LANCETS

- SOLUS V2 28G LANCETS
- SOLUS V2 30G TWIST LANCETS
- SOLUS V2 AUDIBLE TEST STRIPS
- STERILANCE TL TWIST 30G LANCET
- STERILANCE TL TWIST 32G LANCET
- SUPER THIN 28G LANCETS STERILE
- SURE COMFORT 18G LANCETS
- SURE COMFORT 21G LANCETS
- SURE COMFORT 23G LANCETS
- SURE COMFORT 28G LANCETS
- SURE COMFORT 30G LANCETS
- SURE-LANCE 26G LANCETS
- SURE-LANCE FLAT LANCETS
- SURE-LANCE THIN 28G LANCETS
- SURE-LANCE ULTRA THIN 30G
- SURE-TEST EASYPLUS MINI STRIP
- SURE-TOUCH LANCET
- TD GOLD TEST STRIP
- TECHLITE 28G LANCETS
- TECHLITE 30G LANCETS
- TELCARE TEST STRIPS
- TELCARE ULTRA THIN 30G LANCETS
- TEST N'GO GLUCOSE TEST STRIP
- THIN LANCETS 28G
- TOPCARE UNIVERSAL1 33G LANCETS
- TOPCARE UNIVERSAL1 THIN LANCET ULTRA THIN, 30G
- TRUE METRIX GLUCOSE TEST STRIP
- TRUEPLUS 26G LANCETS
- TRUEPLUS 33G LANCETS
- TRUEPLUS SAFETY 28G LANCETS 28G, STERILE
- TRUEPLUS SUPER THIN 28G LANCET 28G, STERILE
- TRUEPLUS ULTRA THIN 30G LANCET
- TRUETEST GLUCOSE TEST STRIPS
- TRUETEST GLUCOSE TEST STRIPS HRI
- TRUETRACK GLUCOSE TEST STRIPS
- ULTILET 28G LANCETS
- ULTILET 30G LANCETS
- ULTILET 33G LANCETS
- ULTILET BASIC 30G LANCETS
- ULTILET CLASSIC 26G LANCETS
- ULTILET CLASSIC 28G LANCETS
- ULTILET CLASSIC 30G LANCETS
- ULTILET CLASSIC 33G LANCETS
- ULTILET SAFETY 23G LANCETS
- ULTIMA TEST STRIPS
- ULTRA THIN 28G LANCETS ULTRA THIN
- ULTRA THIN 31G LANCETS
- ULTRA THIN 33G LANCETS
- ULTRA-THIN II 26G LANCET
- ULTRA-THIN II 28G LANCETS
- ULTRA-THIN II 30G LANCETS
- ULTRALANCE 26G LANCETS
- ULTRALANCE 28G LANCETS
- ULTRATLC LANCETS
- ULTRATRAK TEST STRIP
- ULTRATRAK ULTIMATE TEST STRIPS
- UNILET COMFORTOUCH 26G LANCETS
- UNILET COMFORTOUCH LANCET
- UNILET EXCELITE II LANCET
- UNILET EXCELITE LANCET
- UNILET GP LANCET
- UNILET MICRO THIN 33G LANCETS
- UNILET SUPER THIN 30G LANCETS SINGLE-USE,STERILE
- UNILET ULTRA THIN 28G LANCETS
- UNISTIK 3 COMFORT LANCET
- UNISTIK 3 EXTRA 21G LANCETS
- UNISTIK 3 GENTLE 30G LANCETS
- UNISTIK 3 NORMAL 23G LANCETS
- UNISTIK 3 SAFETY 21G LANCETS
- UNISTIK CZT COMFORT 28G LANCET
- UNISTIK CZT NORMAL 23G LANCETS
- UNISTIK SAFETY 28G LANCET
- UNISTIK SAFETY 30G LANCETS

- UNISTIK TOUCH 21G LANCETS
- UNISTIK TOUCH 23G LANCETS
- UNISTIK TOUCH 28G LANCETS
- UNISTIK TOUCH 30G LANCETS
- UNISTRIP1 GLUCOSE TEST STRIP
- UNIVERSAL 1 33G LANCETS FOR MEIJER
- WALGREENS ULTRA THIN LANCETS
- WAVESENSE JAZZ TEST STRIPS
- WAVESENSE PRESTO TEST STRIPS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	N/A
<b>Other Criteria</b>	<p>COVERAGE OF BLOOD GLUCOSE TEST STRIPS AND LANCETS MAY BE PROVIDED WITH A WRITTEN PRESCRIPTION BY A LICENSED PRACTITIONER TO INPATIENTS RECEIVING NURSING FACILITY LEVEL A (NF-A) SERVICES OR NURSING FACILITY LEVEL B (NF-B) SERVICES, WHETHER OR NOT IN A HOSPITAL SETTING. BLOOD GLUCOSE TEST STRIPS AND LANCETS ARE RESTRICTED TO PATIENTS WITH A DIABETES DIAGNOSIS. BLOOD GLUCOSE TEST STRIPS AND LANCETS PROVIDED TO INPATIENT'S RECEIVING INPATIENT HOSPITAL SERVICES ARE NOT COVERED. REQUESTS THAT DO NOT MEET THE NURSING FACILITY LEVEL A OR LEVEL B CRITERIA WILL BE REVIEWED FOR PART B COVERAGE.</p>

# GLYCEROL PHENYL BUTYRATE

---

## Products Affected

- Ravicti

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TRIAL OF OR CONTRAINDICATION TO SODIUM PHENYL BUTYRATE (BUPHENYL).

# GOLIMUMAB IV

---

## Products Affected

- Simponi ARIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA.

# GOLIMUMAB SQ

## Products Affected

- Simponi

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. ULCERATIVE COLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: RA: 6 MONTHS. PSA/AS: 4 MONTHS. UC: 12 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA OR COSENTYX. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING CONVENTIONAL AGENTS SUCH AS A CORTICOSTEROID (I.E., BUDESONIDE, METHYLPREDINSONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE.

# GUSELKUMAB

## Products Affected

- Tremfya

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL WITH HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA.

# HIGH RISK DRUGS IN THE ELDERLY - ANTICHOLINERGICS - BENZTROPINE\_TRIHEXYPHENIDYL

## Products Affected

- benztropine oral
- trihexyphenidyl

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PREScriBER ACKNOWLEDGEMENT.



# HIGH RISK DRUGS IN THE ELDERLY - ANTICHOLINERGICS - PROMETHAZINE

## Products Affected

- Phenadoz
- promethazine injection solution
- promethazine oral
- promethazine rectal
- Promethegan

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRURITUS/URTICARIA/SEASONAL/PERENNIAL ALLERGY: TRIAL OR CONTRAINDICATION TO A NON-SEDATING ANTIHISTAMINE SUCH AS LEVOCETIRIZINE. NAUSEA AND VOMITING: PRESCRIBER ACKNOWLEDGEMENT OR AWARENESS THAT THE REQUESTED MEDICATION IS CONSIDERED HIGH-RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT TRIAL OF FORMULARY ALTERNATIVES NOR REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY - ANTI- INFECTIVE

## Products Affected

- nitrofurantoin macrocrystal
- nitrofurantoin monohyd/m-cryst

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS. PA REQUIRED FOR PATIENTS 65 YEARS AND OLDER WITH OVER 90 DAYS CUMULATIVE USE OF THE REQUESTED AGENT.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREVIOUS TRIAL OF OR CONTRAINDICATION TO SULFAMETHOXAZOLE/TRIMETHOPRIM (TMP-SMX) OR TRIMETHOPRIM. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING A PREVIOUS TRIAL OF FORMULARY ALTERNATIVES.

# HIGH RISK DRUGS IN THE ELDERLY - BARBITURATE COMBINATIONS

## Products Affected

- Ascomp with Codeine
- Butalbital Compound W/Codeine
- butalbital-acetaminop-caff-cod
- butalbital-acetaminophen oral tablet 50-325 mg
- butalbital-acetaminophen-caff oral capsule 50-325-40 mg
- butalbital-acetaminophen-caff oral tablet 50-325-40 mg
- butalbital-aspirin-caffeine
- Capacet
- Tencon oral tablet 50-325 mg
- Zebutal oral capsule 50-325-40 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY - CARDIOVASCULAR

## Products Affected

- guanfacine oral tablet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	HYPERTENSION: PREVIOUS TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING GENERIC FORMULARY ALTERNATIVES: ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, ANGIOTENSIN RECEPTOR BLOCKER (ARB), ARB COMBINATION, BETA BLOCKER, BETA BLOCKER COMBINATION, OR CALCIUM CHANNEL BLOCKERS. PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING A PREVIOUS TRIAL OF FORMULARY ALTERNATIVES OR PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY - DIGOXIN

## Products Affected

- Digitek oral tablet 125 mcg, 250 mcg
- Digox oral tablet 125 mcg, 250 mcg
- DIGOXIN 0.25 MG/ML SYRINGE
- digoxin injection solution
- digoxin oral solution 50 mcg/mL
- digoxin oral tablet 125 mcg, 250 mcg
- Lanoxin oral tablet 187.5 mcg, 62.5 mcg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	DIGOXIN LEVEL
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	APPROVAL FOR MEMBERS STABLE ON DOSES GREATER THAN 125 MCG PER DAY WITH DOCUMENTED THERAPEUTIC DIGOXIN LEVEL TAKEN WITHIN THE PAST YEAR. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING DIGOXIN LEVELS.

# HIGH RISK DRUGS IN THE ELDERLY - ENDOCRINE - ESTROGEN

## Products Affected

- CombiPatch
- Duavee
- estradiol oral
- estradiol transdermal patch semiweekly
- estradiol transdermal patch weekly
- estradiol-norethindrone acet
- estropipate
- Lopreeza
- Menest oral tablet 0.3 mg, 0.625 mg, 1.25 mg
- Mimvey
- Mimvey Lo
- Premarin oral
- Premphase
- Prempro

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VULVAR/VAGINAL ATROPHY, OSTEOPOROSIS AND VASOMOTOR SYMPTOMS OF MENOPAUSE: PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. ALL OTHER FDA APPROVED INDICATIONS NOT PREVIOUSLY MENTIONED IN THIS SECTION, SUCH AS PALLIATIVE TREATMENT, AND HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY - ENDOCRINE - SULFONYLUREAS

## Products Affected

- glyburide
- glyburide-metformin
- glyburide micronized

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF GLIMEPIRIDE, GLIPIZIDE, OR PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT A TRIAL OF FORMULARY ALTERNATIVES OR PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY - NON-BENZODIAZEPINE

## Products Affected

- eszopiclone
- zolpidem oral tablet
- zaleplon

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS. PA REQUIRED FOR PATIENTS 65 YEARS AND OLDER WITH OVER 90 DAYS CUMULATIVE USE OF NON-BENZODIAZEPINE AGENTS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TRIAL OF SILENOR AND BELSOMRA OR PRESCRIBER ACKNOWLEDGEMENT/ AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING A TRIAL OF FORMULARY ALTERNATIVES (SILENOR AND BELSOMRA) OR PRESCRIBER ACKNOWLEDGEMENT.



# HIGH RISK DRUGS IN THE ELDERLY - SKELETAL MUSCLE RELAXANTS

## Products Affected

- carisoprodol
- chlorzoxazone oral tablet 500 mg
- cyclobenzaprine oral tablet 10 mg, 5 mg
- methocarbamol oral

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- ANTICHOLINERGICS- CYPROHEPTADINE

## Products Affected

- cyproheptadine

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS DRUG IS CONSIDERED A HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING PREScriBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- ANTICHOLINERGICS- DIPHENHYDRAMINE ELIXIR

## Products Affected

- diphenhydramine HCl oral elixir

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ANTIHISTAMINIC CONDITIONS (PRURITUS OR URTICARIA): TRIAL OR CONTRAINDICATION TO A NON-SEDATING ANTIHISTAMINE SUCH AS LEVOCETIRIZINE. INSOMNIA: TRIAL OF SILENOR AND BELSOMRA. ANTIPARKINSONISM: PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS CONSIDERED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT TRIAL OF FORMULARY ALTERNATIVES NOR REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- DIPHENOXYLATE-ATROPINE

---

## Products Affected

- diphenoxylate-atropine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- HYDROXYZINE

## Products Affected

- hydroxyzine HCl intramuscular
- hydroxyzine HCl oral solution 10 mg/5 mL
- hydroxyzine HCl oral tablet
- hydroxyzine pamoate

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS REQUIRE PHYSICIAN ATTESTATION THAT REQUESTED MEDICATION IS USED TO TREAT A DIAGNOSIS UNRELATED TO THE TERMINAL ILLNESS OR RELATED CONDITION, AND ARE APPROVED WITHOUT REQUIRING PREScriBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- INDOMETHACIN

## Products Affected

- indomethacin oral capsule 25 mg, 50 mg                      release
- indomethacin oral capsule, extended

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS LABELED AS HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- KETOROLAC ORAL

---

## Products Affected

- ketorolac oral

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	30 DAYS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- MECLIZINE

## Products Affected

- meclizine oral tablet 12.5 mg, 25 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS CONSIDERED HIGH RISK MEDICATION IN THE ELDERLY FOR PATIENTS 65 YEARS AND OLDER. FOR NAUSEA, VOMITING, AND DIZZINESS ASSOCIATED WITH MOTION SICKNESS: TRIAL OF OR CONTRAINDICATION TO PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE, OR PROCHLORPERAZINE EDISYLATE. HOSPICE PATIENTS REQUIRE PHYSICIAN ATTESTATION THAT REQUESTED MEDICATION IS USED TO TREAT A DIAGNOSIS UNRELATED TO THE TERMINAL ILLNESS OR RELATED CONDITION, AND ARE APPROVED WITHOUT TRIAL OF FORMULARY ALTERNATIVE OR REQUIRING PRESCRIBER ACKNOWLEDGEMENT.



# HIGH RISK DRUGS IN THE ELDERLY- MEGESTROL

## Products Affected

- megestrol oral suspension 400 mg/10 mL (40 mg/mL)
- megestrol oral tablet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- PAROXETINE

## Products Affected

- paroxetine HCl oral tablet release 24 hr
- paroxetine HCl oral tablet extended •

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK DRUGS IN THE ELDERLY- TCA

## Products Affected

- amitriptyline
- amoxapine
- clomipramine
- desipramine
- doxepin oral
- imipramine HCl
- imipramine pamoate
- nortriptyline
- perphenazine-amitriptyline
- protriptyline
- Surmontil
- trimipramine

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT. PRIOR AUTHORIZATION APPLIES TO NEW START ONLY.

# HIGH RISK DRUGS IN THE ELDERLY- BENZODIAZEPINE SEDATIVE HYPNOTICS

## Products Affected

- temazepam oral capsule 15 mg, 30 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS. PA REQUIRED FOR PATIENTS 65 YEARS AND OLDER WITH OVER 90 DAYS CUMULATIVE USE OF THE REQUESTED AGENT.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREVIOUS TRIAL OF OR CONTRAINDICATION TO SILENOR AND BELSOMRA OR PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS LABELED AS HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING A TRIAL OF FORMULARY ALTERNATIVES OR PRESCRIBER ACKNOWLEDGEMENT.

# HIGH RISK MEDICATIONS IN THE ELDERLY- PHENOBARBITAL

## Products Affected

- phenobarbital

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. FOR TREATMENT OF EPILEPSY/SEIZURES IN PATIENTS WHO ARE NOT CURRENTLY STABLE ON PHENOBARBITAL: PATIENT HAS NOT RESPONDED TO OTHER ANTICONVULSANTS. FOR SHORT TERM INSOMNIA: PREVIOUS TRIAL OF OR CONTRAINDICATION TO BELSOMRA AND SILENOR. PATIENTS WHO ARE STABLE ON PHENOBARBITAL FOR EPILEPSY/SEIZURES OR HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING A TRIAL OF FORMULARY ALTERNATIVES OR PRESCRIBER ACKNOWLEDGEMENT.

# HYDROXYPROGESTERONE CAPROATE- DELALUTIN GENERIC

---

## Products Affected

- hydroxyprogesterone caproate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

# IBRUTINIB

---

## Products Affected

- Imbruvica

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# IDELALISIB

---

## Products Affected

- Zydelig

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# IMATINIB MESYLATE

---

## Products Affected

- imatinib oral tablet 100 mg, 400 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ALL DIAGNOSES: 12 MONTHS. ADJUVANT GASTROINTESTINAL STROMAL TUMOR (GIST) TREATMENT: 36 MONTHS.
<b>Other Criteria</b>	PATIENTS WITH PREVIOUSLY-TREATED CML REQUIRE A BCR-ABL MUTATIONAL ANALYSIS CONFIRMING THAT THE PATIENT IS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, V299L, F317L/V/I/C, Y253H, E255K/V, F359V/C/I.

# IMIQUIMOD - ALDARA

---

## Products Affected

- imiquimod

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ACTINIC KERATOSIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST. SUPERFICIAL BASAL CELL CARCINOMA: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR AN ONCOLOGIST.
<b>Coverage Duration</b>	4 MONTHS
<b>Other Criteria</b>	EXTERNAL GENITAL WARTS: TRIAL OF PODOFILOX (CONDYLOX) 0.5% TOPICAL SOLUTION. ACTINIC KERATOSIS BRAND DRUG REQUEST: TRIAL OF GENERIC IMIQUIMOD 5% CREAM. SUPERFICIAL BASAL CELL CARCINOMA: LESS THAN 2CM IN SIZE AND NOT ON THE FACE.

# INFLIXIMAB

## Products Affected

- Remicade

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5 % BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: CD/UC: 8 MO. RA: 6 MO. PSA/AS/PSO: 4 MO. RENEWAL FOR ALL INDICATIONS: 12 MO.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. PSORIATRIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: SIMPONI OR ENTYVIO.</p>

# INFLIXIMAB-ABDA

---

## Products Affected

- Renflexis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: CD/UC: 8 MOS. RA: 6 MOS. PSA/AS/PSO: 4 MOS. RENEWAL FOR ALL INDICATIONS: 12 MOS.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. PSORIATRIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: SIMPONI OR ENTYVIO.</p>

# INFLIXIMAB-DYYB

## Products Affected

- Inflectra

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: PRESCRIBED BY GIVEN OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSORIASIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST. CROHN'S DISEASE/ULCERATIVE COLITIS: GASTROENTEROLOGIST.
Coverage Duration	INITIAL: CD/UC: 8 MOS. RA: 6 MOS. PSA/AS/PSO: 4 MOS. RENEWAL FOR ALL INDICATIONS: 12 MOS.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: ORENCIA, XELJANZ, CIMZIA, OR ACTEMRA. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA, OTEZLA, OR COSENTYX. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: CIMZIA OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY CIMZIA. ULCERATIVE COLITIS (UC): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING: SIMPONI OR ENTYVIO.</p>



# INOTUZUMAB OZOGAMICIN

---

## Products Affected

- Besponsa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# INTERFERON ALFA-2B

---

## Products Affected

- Intron A injection

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HEPATITIS C: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G. HEPATOLOGIST). NO REQUIREMENT FOR OTHER FDA APPROVED INDICATIONS.
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	LIMITED TO 1 YEAR OF THERAPY EXCEPT 18 MONTHS FOR FOLLICULAR LYMPHOMA. HEPATITIS C GENOTYPE 1, 2, 3, 4, 5, OR 6: REQUIRES A TRIAL OF OR CONTRAINDICATION TO PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B USED IN COMBINATION WITH RIBAVIRIN UNLESS CONTRAINDICATED.

# INTERFERONS FOR MS-AVONEX, PLEGRIDY, REBIF

---

## Products Affected

- Avonex (with albumin)
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit
- Plegridy
- Rebif (with albumin)
- Rebif Rebidose
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

# INTERFERONS FOR MS-BETASERON, EXTAVIA

## Products Affected

- Betaseron subcutaneous kit
- Extavia subcutaneous kit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	TRIAL WITH TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, AND GLATIRAMER
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# IPILIMUMAB

## Products Affected

- Yervoy

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: UNRESECTABLE/METASTATIC MELANOMA: 3 MO ADJVNT MELANOMA: 6 MO RENEWAL: ADJVNT MELANOMA: 6 MO
<b>Other Criteria</b>	RENEWAL FOR ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS).

# IVABRADINE

---

## Products Affected

- Corlanor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PATIENT MUST HAVE NEW YORK HEART ASSOCIATION (NYHA) CLASS II TO IV HEART FAILURE
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: APPROVAL REQUIRES THE PATIENT DOES NOT HAVE A DEMAND PACEMAKER SET TO A RATE OF 60 BEATS PER MINUTE OR GREATER. PATIENT IS CURRENTLY RECEIVING TREATMENT WITH OR HAS AN INTOLERANCE TO A FORMULARY BETA BLOCKER SUCH AS METOPROLOL SUCCINATE, BISOPROLOL, OR CARVEDILOL. RENEWAL: APPROVAL REQUIRES DIAGNOSIS OF HEART FAILURE AND PATIENT MUST BE IN SINUS RHYTHM.

# IVACAFITOR

---

## Products Affected

- Kalydeco

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE.
<b>Required Medical Information</b>	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS.
<b>Age Restrictions</b>	6 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# IVACAFTOR - GRANULE PACKETS

---

## Products Affected

- Kalydeco

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	F508DEL MUTATION IN CFTR GENE.
<b>Required Medical Information</b>	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. PATIENT WEIGHT.
<b>Age Restrictions</b>	2 YEARS OF AGE TO 5 YEARS OF AGE
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# IXAZOMIB

---

## Products Affected

- Ninlaro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# IXEKIZUMAB

## Products Affected

- Taltz Autoinjector
- Taltz Syringe

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PLAQUE PSORIASIS (PSO): MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PLAQUE PSORIASIS (PSO): PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST
<b>Coverage Duration</b>	PLAQUE PSORIASIS (PSO): INITIAL: 4 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA.

# LEDIPASVIR-SOFOSBUVIR

## Products Affected

- Harvoni

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, SIMEPREVIR, SOFOSBUVIR (AS A SINGLE AGENT), STRIBILD (ELVITEGRAVIR/COBICISTAT/EMTRICITABINE /TENOFIVIR), OR TIPRANA VIR/RITONA VIR.

# LENALIDOMIDE

---

## Products Affected

- Revlimid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# LENVATINIB MESYLATE

---

## Products Affected

- Lenvima

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# L-GLUTAMINE

---

## Products Affected

- Endari

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	INITIAL CRITERIA FOR ADULTS (18 YEARS OR OLDER): PHYSICIAN ATTESTATION OF ONE OF THE FOLLOWING: (1) AT LEAST 3 SICKLE CELL CRISES IN THE PAST YEAR OR (2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING OR (3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME (ACS). RENEWAL FOR ALL PATIENTS: PHYSICIAN ATTESTATION PATIENT HAS MAINTAINED OR EXPERIENCED REDUCTION IN ACUTE COMPLICATIONS OF SICKLE CELL DISEASE.

# LIDOCAINE

---

## Products Affected

- lidocaine topical adhesive patch,medicated
- lidocaine topical ointment

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL COVERAGE FOR DIABETIC NEUROPATHY WILL BE CONSIDERED FOR REQUESTS FOR LIDOCAINE TOPICAL PATCHES.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	PATCH: 12 MONTHS. OINTMENT: 3 MONTHS.
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# LOMITAPIDE

---

## Products Affected

- Juxtapid oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 5 mg, 60 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LDL CHOLESTEROL LEVEL, LDL RECEPTOR STATUS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST.
<b>Coverage Duration</b>	INITIAL: 7 MONTHS RENEWAL: 6 MONTHS



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING: SIMON BROOME DIAGNOSTIC CRITERIA (DEFINITE), (E.G. GENETIC TESTING CONSISTENT WITH HOFH AND PRETREATMENT BASELINE LDL CHOLESTEROL IS GREATER THAN 190 MG/DL), CASCADE SCREENING, DUTCH LIPID NETWORK CRITERIA WITH A SCORE OF AT LEAST 6, OR HISTORY OF UNTREATED CHOLESTEROL GREATER THAN 500MG/DL (OR TREATED CHOLESTEROL GREATER THAN 300MG/DL) AND CUTANEOUS XANTHOMA BEFORE 10 YEARS OF AGE. LOMITAPIDE WILL NOT BE APPROVED FOR PATIENTS CONCURRENTLY USING ANY OF THE FOLLOWING STRONG OR MODERATE CYP3A4 MEDICATIONS: CLARITHROMYCIN, CONIVAPTAN, INDINAVIR, ITRACONAZOLE, KETOCONAZOLE, LOPINAVIR/RITONAVIR, MIBEFRADIL, NEFAZODONE, NELFINAVIR, POSACONAZOLE, RITONAVIR, SAQUINAVIR, TELITHROMYCIN, TIPRANAVIR/RITONAVIR, VORICONAZOLE, AMPRENAVIR, APREPITANT, ATAZANAVIR, CIPROFLOXACIN, CRIZOTINIB, DARUNAVIR/RITONAVIR, DILTIAZEM, ERYTHROMYCIN, FLUCONAZOLE, FOSAMPRENAVIR, IMATINIB, OR VERAPAMIL. INITIAL: LDL CHOLESTEROL LEVEL OF AT LEAST 160MG/DL WHILE ON LIPID-LOWERING THERAPY PRIOR TO INITIATING LOMITAPIDE. PREVIOUS TRIAL OF A PCSK9 INHIBITOR (E.G. ALIROCUMAB OR EVOLOCUMAB), UNLESS THE PATIENT HAS NON-FUNCTIONING LDL RECEPTORS. PREVIOUS TRIAL OF ROSUVASTATIN OR ATORVASTATIN, UNLESS THE PATIENT HAS AN ABSOLUTE CONTRAINDICATION TO STATIN THERAPY (E.G. ACTIVE, DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT, HYPERSENSITIVITY REACTION). STATIN-TOLERANT PATIENTS MUST BE TAKING ATORVASTATIN OR ROSUVASTATIN FOR THE PAST 2 MONTHS PRIOR TO STARTING LOMITAPIDE. LOMITAPIDE MUST BE USED IN COMBINATION WITH ATORVASTATIN OR ROSUVASTATIN. IF THE PATIENT HAS PREVIOUSLY TRIED ATORVASTATIN OR ROSUVASTATIN, LOMITAPIDE MUST BE USED IN COMBINATION WITH ANOTHER STATIN OR FORMULARY LDL-LOWERING AGENT (E.G. BILE ACID SEQUESTRANT, GEMFIBROZIL OR OTHER FIBRATE, EZETIMIBE, OR NIACIN). STATIN-INTOLERANT PATIENTS REQUIRE EITHER PHYSICIAN ATTESTATION OF</p>

PA Criteria	Criteria Details
	<p>STATIN INTOLERANCE OR HISTORY OF SKELETAL-MUSCLE RELATED SYMPTOMS (E.G., MYOPATHY) DUE TO A PREVIOUS TRIAL OF STATINS (E.G. ROSUVASTATIN OR ATORVASTATIN). FOR STATIN-INTOLERANT PATIENTS, LOMITAPIDE MUST BE USED IN COMBINATION WITH ONE OF THE FOLLOWING FORMULARY LIPID-LOWERING TREATMENTS: EZETIMIBE, FENOFIBRATE, NIACIN, OR A BILE ACID SEQUESTRANT (E.G. CHOLESTYRAMINE, COLESTIPOL, COLESEVELAM). RENEWAL: PATIENT HAS RECEIVED AT LEAST 6 MONTHS OF THERAPY WITH LOMITAPIDE IN COMBINATION WITH ANOTHER AND LIPID-LOWERING AGENT.</p>

# LUMACAFITOR-IVACAFITOR

---

## Products Affected

- Orkambi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. BASELINE FEV1.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL 12 MONTHS.
<b>Other Criteria</b>	RENEWAL: MAINTAINED OR IMPROVEMENT IN FEV1 OR REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS OR IMPROVEMENT IN BODY MASS INDEX (BMI).

# MEPOLIZUMAB

## Products Affected

- Nucala

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	CONCURRENT USE OF XOLAIR
<b>Required Medical Information</b>	BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 150 CELLS/MCL WITHIN THE LAST 6 WEEKS OR GREATER THAN OR EQUAL TO 300 CELLS/MCL WITHIN THE LAST 12 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY MEDICINE, AN ALLERGIST OR AN IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL 24 WEEKS. RENEWAL 12 MONTHS
<b>Other Criteria</b>	INITIAL THERAPY: PATIENT CURRENTLY TREATED WITH A MAXIMALLY TOLERATED DOSE OF INHALED CORTICOSTEROIDS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION WHICH INCLUDES ANY OF THE FOLLOWING: LONG-ACTING INHALED BETA2-AGONIST, LONG-ACTING MUSCARINIC ANTAGONIST, A LEUKOTRIENE RECEPTOR ANTAGONIST, THEOPHYLLINE, OR ORAL CORTICOSTEROID. RENEWAL REQUIRES DOCUMENTATION THAT THE PATIENT HAS EXPERIENCED IMPROVEMENT IN ASTHMA EXACERBATIONS FROM BASELINE (PHYSICIAN ATTESTATION) AND A REDUCTION IN ORAL CORTICOSTEROID DOSE (IF THE PATIENT WAS ON A MAINTENANCE REGIMEN OF ORAL CORTICOSTEROIDS AT THE INITIATION OF TREATMENT).

# METHYLNALTREXONE

## Products Affected

- Relistor subcutaneous solution
- Relistor subcutaneous syringe

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ADVANCED ILLNESS: OPIOID-INDUCED CONSTIPATION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS FOR PATIENTS RECEIVING PALLIATIVE CARE, 12 MONTHS FOR PATIENTS WITH CHRONIC, NON-CANCER PAIN.
<b>Other Criteria</b>	ADVANCED ILLNESS: PATIENT IS RECEIVING PALLIATIVE CARE. CHRONIC NON-CANCER PAIN: PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS AND HAD A PREVIOUS TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK).

# METHYLNALTREXONE ORAL

---

## Products Affected

- Relistor oral

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS AND HAD A PREVIOUS TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK).

# MIDOSTAURIN

---

## Products Affected

- Rydapt

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
<b>Other Criteria</b>	

# MIFEPRISTONE

---

## Products Affected

- Korlym

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# MILTEFOSINE

---

## Products Affected

- Impavido

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# MIPOMERSEN

---

## Products Affected

- Kynamro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LDL CHOLESTEROL LEVEL, LDL RECEPTOR STATUS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST, ENDOCRINOLOGIST OR LIPIDOLOGIST
<b>Coverage Duration</b>	INITIAL: 7 MONTHS RENEWAL 12 MONTHS

PA Criteria	Criteria Details
Other Criteria	<p>DIAGNOSIS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS DETERMINED BY ONE OF THE FOLLOWING CRITERIA: SIMON BROOME DIAGNOSTIC CRITERIA (DEFINITE) [EXAMPLE: GENETIC TESTING CONSISTENT WITH HOFH AND PRETREATMENT BASELINE LDL CHOLESTEROL IS GREATER THAN 190 MG/DL], CASCADE SCREENING, DUTCH LIPID NETWORK CRITERIA WITH A SCORE AT LEAST 6, OR HISTORY OF UNTREATED CHOLESTEROL GREATER THAN 500MG/DL (OR TREATED GREATER THAN 300MG/DL) AND CUTANEOUS XANTHOMA BEFORE AGE 10. INITIAL CRITERIA: CURRENT LDL CHOLESTEROL LEVEL IS AT LEAST 160MG/DL. PATIENT DOES NOT HAVE ANY OF THE FOLLOWING CONTRAINDICATIONS TO KYNAMRO (MIPOMERSEN): MODERATE OR SEVERE HEPATIC IMPAIRMENT OR ACTIVE LIVER DISEASE, INCLUDING UNEXPLAINED PERSISTENT ELEVATIONS OF SERUM TRANSAMINASES. PREVIOUS TRIAL OF A PCSK9 INHIBITOR (SUCH AS ALIROCUMAB OR EVOLOCUMAB) UNLESS THE PATIENT HAS NON-FUNCTIONING LDL RECEPTORS. PREVIOUS TRIAL WITH ONE OF THE FOLLOWING STATINS: ROSUVASTATIN OR ATORVASTATIN. PATIENTS WITH ABSOLUTE CONTRAINDICATION TO STATIN THERAPY (ACTIVE, DECOMPENSATED LIVER DISEASE, NURSING FEMALE, PREGNANCY OR PLANS TO BECOME PREGNANT, HYPERSENSITIVITY REACTION) WILL BE APPROVED FOR THERAPY WITHOUT REQUIREMENT OF A TRIAL WITH A STATIN. STATIN-TOLERANT PATIENTS: PRIOR TO (KYNAMRO), PATIENT MUST HAVE BEEN TAKING ONE OF THE FOLLOWING: ATORVASTATIN OR ROSUVASTATIN, FOR AT LEAST 2 MONTHS WITHIN THE PAST 2 MONTHS. FOR STATIN-INTOLERANT PATIENTS: DOCUMENTATION OF STATIN INTOLERANCE WHICH INCLUDES THE FOLLOWING: PHYSICIAN ATTESTATION OR PATIENT HAS TRIED ROSUVASTATIN OR ATORVASTATIN AND HAS EXPERIENCED SKELETAL-MUSCLE RELATED SYMPTOMS (E.G., MYOPATHY). UNLESS CONTRAINDICATED, PATIENT MUST BE ON CONCURRENT THERAPY WITH ONE OF THE FOLLOWING LIPID-LOWERING TREATMENTS (SUCH AS A STATIN [SIMVASTATIN, ATORVASTATIN], EZETIMIBE, FENOFIBRATE, NIACIN, OR BILE ACID SEQUESTRANT [CHOLESTYRAMINE, COLESTIPOL, COLESEVELAM]). RENEWAL CRITERIA:</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
	PATIENT HAS RECEIVED THERAPY FOR AT LEAST 6 MONTHS AND MUST ALSO BE TAKING KYNAMRO IN COMBINATION WITH ANOTHER LIPID-LOWERING AGENT.

# MODAFINIL AND ARMODAFINIL

---

## Products Affected

- armodafinil

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# NATALIZUMAB

## Products Affected

- Tysabri

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CROHN'S DISEASE: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	MULTIPLE SCLEROSIS: 12 MONTHS. CROHN'S DISEASE: INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MULTIPLE SCLEROSIS INITIAL CRITERIA: PREVIOUS TRIAL OF TWO OF THE FOLLOWING PREFERRED AGENTS FOR MULTIPLE SCLEROSIS: GLATIRAMER, REBIF, AVONEX, PLEGRIDY, TECFIDERA, GILENYA, OR AUBAGIO. CROHN'S DISEASE INITIAL CRITERIA: PREVIOUS TRIAL OF HUMIRA AND CIMZIA. CROHN'S DISEASE RENEWAL CRITERIA: PATIENT HAS RECEIVED AT LEAST 12 MONTHS OF THERAPY WITH TYSABRI WITH PHYSICIAN ATTESTATION THAT THE PATIENT HAS NOT REQUIRED MORE THAN 3 MONTHS OF CORTICOSTEROID USE WITHIN THE PAST 12 MONTHS TO CONTROL THEIR CROHN'S DISEASE WHILE ON TYSABRI, OR PATIENT HAS ONLY RECEIVED 6 MONTHS OF THERAPY WITH TYSABRI WITH PHYSICIAN ATTESTATION THAT THE PATIENT HAS TAPERED OFF CORTICOSTEROIDS DURING THE FIRST 24 WEEKS OF TYSABRI THERAPY.

# NECITUMUMAB

---

## Products Affected

- Portrazza

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# NERATINIB MALEATE

---

## Products Affected

- Nerlynx

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	EARLY-STAGE TUMOR (STAGE I-III) AND TUMOR IS HORMONE-RECEPTOR POSITIVE AND THE MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE



# NILOTINIB

---

## Products Affected

- Tasigna

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PREVIOUSLY TREATED CML REQUIRES BCR-ABL MUTATIONAL ANALYSIS NEGATIVE FOR THE FOLLOWING MUTATIONS: T315I, Y253H, E255K/V, AND F359V/C/I.

# NINTEDANIB

## Products Affected

- Ofev

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	NOT APPROVED FOR PATIENTS WITH OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, AND CANCER. NOT APPROVED IF PATIENT DOES NOT HAVE A PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50 PERCENT OR HAS NOT OBTAINED LIVER FUNCTION TESTS
<b>Required Medical Information</b>	A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PULMONOLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# NIRAPARIB TOSYLATE

---

## Products Affected

- Zejula

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# NITISINONE

---

## Products Affected

- Orfadin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	DIAGNOSIS OF HEREDITARY TYROSINEMIA TYPE 1 AS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	ORFADIN SUSPENSION: TRIAL OF ORFADIN CAPSULES. RENEWAL: THE PATIENT'S URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.

# NIVOLUMAB

---

## Products Affected

- Opdivo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MELANOMA: OPDIVO IS NOT APPROVED FOR COMBINATION THERAPY WITH TAFINLAR, MEKINIST (TRAMETINIB), COTELLIC (COBIMETINIB), OR ZELBORAF.

# OBETICHOLIC ACID

## Products Affected

- Ocaliva

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	PATIENTS WITH COMPLETE BILIARY OBSTRUCTION.
<b>Required Medical Information</b>	DIAGNOSIS OF PRIMARY BILIARY CHOLANGITIS AS CONFIRMED BY AT LEAST TWO OF THE FOLLOWING CRITERIA: AN ALKALINE PHOSPHATASE LEVEL OF AT LEAST 1.5 TIMES THE UPPER LIMIT OF NORMAL (ULN), THE PRESENCE OF ANTIMITOCHONDRIAL ANTIBODIES AT A TITER OF 1:40 OR HIGHER, HISTOLOGIC EVIDENCE OF NON-SUPPURATIVE DESTRUCTIVE CHOLANGITIS AND DESTRUCTION OF INTERLOBULAR BILE DUCTS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST OR HEPATOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	INITIAL: USED IN COMBINATION WITH URSODEOXYCHOLIC ACID (E.G., URSODIOL, URSO 250, URSO FORTE) IN ADULTS WITH AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID AT A DOSAGE OF 13-15 MG/KG/DAY FOR AT LEAST 1 YEAR, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE URSODEOXYCHOLIC ACID. RENEWAL: PATIENT'S ALKALINE PHOSPHATASE LEVELS HAVE DECREASED BY AT LEAST 15% FROM BASELINE WHILE ON TREATMENT WITH OBETICHOLIC ACID.

# OBINUTUZUMAB

---

## Products Affected

- Gazyva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	

# OCRELIZUMAB

---

## Products Affected

- Ocrevus

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS: TRIAL OF TWO OF THE FOLLOWING AGENTS FOR MULTIPLE SCLEROSIS: AUBAGIO, AVONEX, GILENYA, PLEGRIDY, REBIF, TECFIDERA, OR GLATIRAMER. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.



# OLAPARIB

---

## Products Affected

- Lynparza oral capsule
- Lynparza oral tablet

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# OLARATUMAB

---

## Products Affected

- Lartruvo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.

# OMACETAXINE

## Products Affected

- Synribo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INDUCTION: 3 MONTHS. POST INDUCTION OR RENEWAL: 3 TO 12 MONTHS
Other Criteria	CML INDUCTION THERAPY: TRIAL OF OR CONTRAINDICATION TO AT LEAST TWO OF THE FOLLOWING AGENTS: GLEEVEC, SPRYCEL, TASIGNA, BOSULIF OR ICLUSIG. APPROVAL FOR POST-INDUCTION THERAPY DURATION WILL DEPEND ON THE PATIENT'S HEMATOLOGIC RESPONSE, DEFINED AS AN ABSOLUTE NEUTROPHIL COUNT (ANC) GREATER THAN OR EQUAL TO $1.5 \times 10^9/L$ , PLATELETS GREATER THAN OR EQUAL TO $100 \times 10^9/L$ WITHOUT BLOOD BLASTS OR THE PATIENT HAS BONE MARROW BLASTS AT LESS THAN 5 PERCENT. APPROVAL IS FOR 12 MONTHS IF HEMATOLOGIC RESPONSE IS MET. IF NOT MET, APPROVAL IS FOR 3 MONTHS.

# OMALIZUMAB

## Products Affected

- Xolair

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL CRITERIA FOR ASTHMA: PATIENT MEETS THE CRITERIA OF MODERATE TO SEVERE ASTHMA, POSITIVE SKIN PRICK OR RAST TEST, FEV1 LESS THAN 80%, DEMONSTRATED INADEQUATELY CONTROLLED SYMPTOMS ON INHALED CORTICOSTEROIDS AND SECOND ASTHMA CONTROLLER, BASELINE IGE SERUM LEVEL GREATER THAN OR EQUAL TO 30IU/ML. RENEWAL CRITERIA FOR ASTHMA: PHYSICIAN ATTESTATION OF IMPROVEMENT IN ASTHMA EXCERBATIONS FROM BASELINE AND A REDUCTION IN ORAL OR INHALED CORTICOSTEROID USE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A SPECIALIST IN ALLERGY, PULMONARY MEDICINE, DERMATOLOGY OR IMMUNOLOGY.
<b>Coverage Duration</b>	ASTHMA: 12 MONTHS. CHRONIC IDIOPATHIC URTICARIA: 6 MONTHS.
<b>Other Criteria</b>	FOR CHRONIC IDIOPATHIC URTICARIA: PREVIOUS TRIAL OF OR CONTRAINDICATION TO A MAXIMALLY TOLERATED DOSE OF AN H1 ANTI-HISTAMINE (SUCH AS CLARINEX OR XYZAL) AND PATIENT STILL EXPERIENCES HIVES ON MOST DAYS OF THE WEEK.

# OMBITASVIR-PARITAPREVIR-RITONAVIR

## Products Affected

- Technivie

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	DECOMPENSATED CIRRHOSIS, MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD-PUGH B OR C).
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. MUST BE USED CONCURRENTLY WITH RIBAVIRIN UNLESS PATIENT IS TREATMENT NAIVE AND HAS CONTRAINDICATION TO RIBAVIRIN. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER): ALFUZOSIN, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, RIFAMPIN, ERGOTAMINE, DIHYDROERGOTAMINE, ERGONOVINE, METHYLERGONOVINE, ETHINYL ESTRADIOL CONTAINING MEDICATIONS (SUCH AS COMBINED ORAL CONTRACEPTIVES, NUVARING, ORTHO EVRA OR XULANE TRANSDERMAL PATCH SYSTEM), LOVASTATIN, SIMVASTATIN, PIMOZIDE, EFAVIRENZ (ATRIPLA, SUSTIVA), REVATIO (SILDENAFIL DOSE OF 20MG AND/OR DOSED THREE TIMES DAILY FOR PAH), TRIAZOLAM, ORAL MIDAZOLAM, LOPINAVIR/RITONAVIR, RILPIVIRINE, SALMETEROL.</p>

# OMBITASVIR-PARITAPREVIR-RITONAVIR-DASABUVIR

## Products Affected

- Viekira Pak
- Viekira XR

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
Exclusion Criteria	DECOMPENSATED CIRRHOSIS, MODERATE OR SEVERE LIVER IMPAIRMENT (CHILD-PUGH B OR C).
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: ALFUZOSIN, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, GEMFIBROZIL, RIFAMPIN, ERGOTAMINE, DIHYDROERGOTAMINE, ERGONOVINE, METHYLERGONOVINE, ETHINYL ESTRADIOL CONTAINING MEDICATIONS (SUCH AS COMBINED ORAL CONTRACEPTIVES, NUVARING, ORTHO EVRA OR XULANE TRANSDERMAL PATCH SYSTEM), ST. JOHN'S WORT, LOVASTATIN, SIMVASTATIN, PIMOZIDE, EFAVIRENZ, REVATIO, TRIAZOLAM, ORAL MIDAZOLAM, DARUNAVIR/RITONAVIR, LOPINAVIR/RITONAVIR, RILPIVIRINE, SALMETEROL.</p>



# OSIMERTINIB

---

## Products Affected

- Tagrisso

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# OXYMETHOLONE

---

## Products Affected

- Anadrol-50

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, WOMEN WHO ARE OR MAY BECOME PREGNANT, NEPHROSIS OR THE NEPHROTIC PHASE OF NEPHRITIS, HYPERSENSITIVITY TO THE DRUG AND SEVERE HEPATIC DYSFUNCTION.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PALBOCICLIB

---

## Products Affected

- Ibrance

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PREVIOUS TRIAL OF OR CONTRAINDICATION TO THE PREFERRED FORMULARY ALTERNATIVE RIBOCICLIB (KISQALI).

# PALIVIZUMAB

## Products Affected

- Synagis

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	GESTATIONAL AGE
Age Restrictions	LESS THAN 24 MONTHS OF AGE.
Prescriber Restrictions	
Coverage Duration	1 MONTH TO 5 MONTHS. SEE OTHER CRITERIA FOR MORE INFORMATION.
Other Criteria	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT RECOMMENDATIONS FROM THE AMERICAN ACADEMY OF PEDIATRICS FOR PALIVIZUMAB PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS INFECTIONS. INITIAL: APPROVAL WILL BE FOR AT LEAST 1 MONTH AND NO GREATER THAN 5 MONTHS DEPENDENT UPON REMAINING LENGTH OF RESPIRATORY SYNCYTIAL VIRUS (RSV) SEASON. RENEWAL: ADDITIONAL 1 MONTH OF TREATMENT FOR CARDIOPULMONARY BYPASS SURGERY DURING RSV PROPHYLAXIS SEASON.

# PANOBINOSTAT

---

## Products Affected

- Farydak

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RENEWAL: PATIENT HAS TOLERATED THE FIRST 8 CYCLES OF THERAPY WITHOUT UNRESOLVED SEVERE OR MEDICALLY SIGNIFICANT TOXICITY.

# PARATHYROID HORMONE

---

## Products Affected

- Natpara

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PAZOPANIB

---

## Products Affected

- Votrient

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION

## Products Affected

- Adcirca
- sildenafil (antihypertensive) oral

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	PATIENT CANNOT CONCURRENTLY OR INTERMITTENTLY BE TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA), ANY ORGANIC NITRATES IN ANY FORM, OR GUANYLATE CYCLASE (GC) STIMULATORS (ADEMPAS).
<b>Required Medical Information</b>	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. REQUEST FOR ADCIRCA REQUIRE TRIAL OR CONTRAINDICATION TO REVATIO. RENEWAL: PATIENT SHOWS IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.



# PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION - IV

## Products Affected

- sildenafil (antihypertensive) intravenous

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	PATIENT CANNOT CONCURRENTLY OR INTERMITTENTLY BE TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA), ANY ORGANIC NITRATES IN ANY FORM, OR GUANYLATE CYCLASE (GC) STIMULATORS (ADEMPAS).
<b>Required Medical Information</b>	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT SHOWS IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

# PEDIATRIC VITAMINS

---

## Products Affected

- POLY-VITA WITH IRON DROPS
- POLYVITAMIN W-IRON DROPS
- TRI-VI-SOL DROPS
- TRI-VITA DROPS
- TRI-VITAMIN DROPS

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	N/A
Other Criteria	REIMBURSABLE FOR CHILDREN UP TO THE 5TH BIRTHDAY ONLY.

# PEG-INTERFERON ALFA-2B-SYLATRON

---

## Products Affected

- Sylatron

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	OVERALL DURATION OF THERAPY LIMITED TO 5 YEARS.

# PEMBROLIZUMAB

---

## Products Affected

- Keytruda intravenous recon soln
- Keytruda intravenous solution

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PENICILLAMINE

## Products Affected

- Cuprimine

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	RHEUMATOID ARTHRITIS: HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	WILSON'S DISEASE: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEPATOLOGIST. CYSTINURIA: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	WILSON'S DISEASE: GENETIC TESTING FOR ATP7B MUTATIONS. CYSTINURIA: DIAGNOSIS REQUIRES THE PRESENCE OF NEPHROLITHIASIS AND 1 OR MORE OF THE FOLLOWING: STONE ANALYSIS SHOWING PRESENCE OF CYSTEINE, IDENTIFICATION OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, POSITIVE FAMILY HISTORY OF CYSTINURIA WITH POSITIVE CYANIDE-NITROPRUSSIDE SCREEN. REQUESTS FOR CUPRIMINE FOR THE TREATMENT OF WILSONS DISEASE, CYSTINURIA, AND RHEUMATOID ARTHRITIS REQUIRE A PREVIOUS TRIAL OF OR CONTRAINDICATION TO DEPEN.

# PENICILLAMINE-DEPEN

## Products Affected

- Depen Titratabs

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	RHEUMATOID ARTHRITIS: HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	WILSON'S DISEASE: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEPATOLOGIST. CYSTINURIA: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	WILSON'S DISEASE: GENETIC TESTING FOR ATP7B MUTATIONS. CYSTINURIA: DIAGNOSIS REQUIRES THE PRESENCE OF NEPHROLITHIASIS AND 1 OR MORE OF THE FOLLOWING: STONE ANALYSIS SHOWING PRESENCE OF CYSTEINE, IDENTIFICATION OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, POSITIVE FAMILY HISTORY OF CYSTINURIA WITH POSITIVE CYANIDE-NITROPRUSSIDE SCREEN.

# PIMAVANSERIN

---

## Products Affected

- Nuplazid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (SUCH AS A PSYCHIATRIST).
<b>Coverage Duration</b>	INITIAL 12 MONTHS. RENEWAL 12 MONTHS.
<b>Other Criteria</b>	RENEWAL REQUIRES THAT THE PATIENT HAS EXPERIENCED AN IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.

# PIRFENIDONE

## Products Affected

- Esbriet oral capsule
- Esbriet oral tablet 267 mg, 801 mg

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	PATIENTS WITH KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, AND CANCER). NOT APPROVED IF THE PATIENT HAS NOT OBTAINED LIVER FUNCTION TESTS.
<b>Required Medical Information</b>	PATIENT WITH USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PULMONOLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PATIENT HAS A PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50%.



# POMALIDOMIDE

---

## Products Affected

- Pomalyst

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PONATINIB

---

## Products Affected

- Iclusig oral tablet 15 mg, 45 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PRAMLINTIDE

---

## Products Affected

- SymlinPen 120
- SymlinPen 60

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	TYPE I OR TYPE II DIABETES: REQUIRING INSULIN OR CONTINUOUS INSULIN INFUSION (INSULIN PUMP) FOR GLYCEMIC CONTROL
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# PRENATAL OTC VITAMINS

## Products Affected

- CVS PRENATAL GUMMY VITAMINS SFGL
- CVS PRENATAL MULTI-DHA SOFTGEL
- CVS PRENATAL VITAMIN TABLET
- CVS WOMEN'S PRENATAL + DHA
- DAILY PRENATAL COMBO PACK
- EXPECTA PRENATAL COMBO PACK
- KPN TABLET
- KRO PRENATAL VITAMINS TABLET
- ONE A DAY PRENATAL DHA PACK 30 LIQ GELS,30 TABS
- ONE-A-DAY PRENATAL 1 DHA SFGL
- PERRY PRENATAL CAPSULE
- PRENATAL + DHA COMBO PACK
- PRENATAL 19 CHEWABLE TABLET (OTC)
- PRENATAL FORMULA TABLET
- PRENATAL GUMMIES
- PRENATAL MULTI + DHA SOFTGEL P/F, GLUTEN-FREE
- PRENATAL MULTIVITAMIN TABLET
- PRENATAL MULTIVITAMIN-DHA
- PRENATAL ONE TABLET
- PRENATAL TABLET
- PRENATAL TABLET (OTC)
- PRENATAL TABLET OUTER (OTC)
- PRENATAL VITAMIN TABLET
- PRENATAL VITAMINS TABLET PHOSPHORUS FREE
- RA ONE DAILY PRENATAL DHA PACK 30'S TAB & 30'S CAP
- RA PRENATAL TABLET
- RIGHT STEP PRENATAL VIT TAB
- SIMILAC PRENATAL COMBO PACK
- SM ONE DAILY PRENATAL COMBO PK
- SM PRENATAL VITAMINS TABLET
- STUART ONE CAPSULE
- THERANATAL CORE NUTRITION TAB
- THERANATAL OVAVITE COMBO PACK
- THERANATAL PLUS COMBO PACK
- VINACAL B PRENATAL COMBO PACK

PA Criteria	Criteria Details
Covered Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	N/A
<b>Other Criteria</b>	RESTRICTED TO USE BY EXPECTANT FEMALES WITH CONFIRMED POSITIVE PREGNANCY TEST CONDUCTED BY HER PHYSICIAN.

# PYRIMETHAMINE

---

## Products Affected

- Daraprim

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D, ADDITIONAL CONSIDERATION FOR CHRONIC MAINTENANCE THERAPY FOR TOXOPLASMOSIS AND TOXOPLASMOSIS PROPHYLAXIS.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALARIA: PLASMODIA SUSCEPTIBLE TESTING. TOXOPLASMOSIS:CD4 LEVEL
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE MALARIA AND CHEMOPROPHYLAXIS: INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS. SEE OTHER CRITERIA FIELD

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: ACUTE MALARIA TREATMENT AND MALARIA CHEMOPROPHYLAXIS REQUIRES THAT THE PATIENT HAS MALARIA SUSCEPTIBLE TO PYRIMETHAMINE AND A PREVIOUS TRIAL OF PLAQUENIL (HYDROXYCHLOROQUINE SULFATE) AND MALARONE (ATOVAQUONE/PROGUANIL) (UNLESS THESE REGIMENS ARE RESISTANT IN THE SPECIFIC REGION AS INDICATED BY REGIONAL PLASMODIA SUSCEPTIBILITY). PRIMARY PROPHYLAXIS OF TOXOPLASMOSIS IN PATIENTS WITH HIV REQUIRES PREVIOUS TRIAL OF OR CONTRAINDICATION TO BACTRIM (SMX/TMP). RENEWAL: CONTINUATION OF TREATMENT FOLLOWING ACUTE MALARIA REQUIRES PREVIOUS INFECTION WITH MALARIA SUSCEPTIBLE TO PYRIMETHAMINE WITH SUBSEQUENT CLINICAL CURE (ELIMINATION OF MALARIA SYMPTOMS DEFINED AS CHILLS, FEVER, SWEATS, GENERAL MALAISE) FOLLOWED BY SYMPTOMS OF RELAPSE. CONTINUATION OF MALARIA CHEMOPROPHYLAXIS REQUIRES THE PATIENT WILL BE TRAVELING TO OR RESIDING IN AN AREA WHERE PLASMODIA SUSCEPTIBLE TO PYRIMETHAMINE EXISTS (MALARIA MUST BE SENSITIVE TO PYRIMETHAMINE).CONTINUED TREATMENT OF TOXOPLASMOSIS REQUIRES ONE OF THE FOLLOWING: 1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING) OR 2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENT ANTI-RETROVIRAL THERAPY IF HIV POSITIVE. CONTINUATION OF PRIMARY PROPHYLAXIS FOR TOXOPLASMOSIS WITH HIV REQUIRES CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENT ANTI RETROVIRAL THERAPY. TOXOPLASMOSIS: INITIAL: 8 WEEKS. RENEWAL: 6 MONTHS. PRIMARY PROPHYLAXIS OF TOXOPLASMOSIS: INITIAL AND RENEWAL IS 12 MONTHS.</p>

# QUININE SULFATE

---

## Products Affected

- quinine sulfate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# RAMUCIRUMAB

---

## Products Affected

- Cynamza

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# REGORAFENIB

## Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOR COLORECTAL CANCER: TRIAL OF OR CONTRAINDICATION TO AN ANTI-VEGF THERAPY SUCH AS AVASTIN OR ZALTRAP AND A FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY SUCH AS FOLFOX, FOLFOXIRI, FOLFIRI, CAPEOX, INFUSIONAL 5-FU/LV OR CAPECITABINE. IF APPLICABLE, A TRIAL OF OR CONTRAINDICATION TO AN ANTI-EGFR THERAPY SUCH AS ERBITUX OR VECTIBIX IS ALSO REQUIRED FOR KRAS WILD TYPE COLORECTAL CANCER. FOR GIST, A TRIAL OF OR CONTRAINDICATION TO GLEEVEC AND SUTENT IS REQUIRED.

# RESLIZUMAB

---

## Products Affected

- Cinqair

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	CONCURRENT USE OF XOLAIR
<b>Required Medical Information</b>	BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 400 CELLS/MCL WITHIN THE LAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY MEDICINE
<b>Coverage Duration</b>	INITIAL 24 WEEKS. RENEWAL 12 MONTHS
<b>Other Criteria</b>	INITIAL THERAPY: PATIENT CURRENTLY TREATED WITH A MAXIMALLY TOLERATED DOSE OF INHALED CORTICOSTEROIDS. RENEWAL REQUIRES DOCUMENTATION THAT THE PATIENT HAS EXPERIENCED AT LEAST A 25 PERCENT REDUCTION IN ASTHMA EXACERBATIONS (FOR EXAMPLE: HOSPITALIZATIONS, URGENT OR EMERGENT CARE VISITS, USE OF RESCUE MEDICATIONS, ETC.) FROM BASELINE.

# RIBOCICLIB

---

## Products Affected

- Kisqali mg/day(200 mg x 2)-2.5 mg, 600
- Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 3)-2.5 mg  
mg/day(200 mg x 1)-2.5 mg, 400

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# RIFAXIMIN

---

## Products Affected

- Xifaxan oral tablet 200 mg, 550 mg

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS' DIARRHEA:1 FILL IN 1MONTH.HEPATIC ENCEPHALOPATHY:12 MO.IBS-D:INITIAL:12 WKS.RENEWAL:12 MO
Other Criteria	FOR RIFAXIMIN 550 MG TABLETS ONLY: INITIAL: HEPATIC ENCEPHALOPATHY (HE): PREVIOUS TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY. IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D): PREVIOUS TRIAL OF OR CONTRAINDICATION TO DICYCLOMINE. RENEWAL FOR IBS-D REQUIRES THAT AT LEAST 10 WEEKS HAVE PASSED SINCE THE LAST TREATMENT COURSE OF RIFAXIMIN AND PHYSICIAN ATTESTATION OF IMPROVEMENT.

# RIOCIGUAT

## Products Affected

- Adempas

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	INITIAL FOR PAH: PATIENT IS NOT CONCURRENTLY TAKING NITRATES OR NITRIC OXIDE DONORS (E.G. AMYL NITRATE), PHOSPHODIESTERASE INHIBITORS (E.G. SILDENAFIL, TADALAFIL, OR VARDENAFIL), OR NON-SPECIFIC PDE INHIBITORS (E.G. DIPYRIDAMOLE, THEOPHYLLINE). INITIAL FOR CTEPH: PATIENT IS NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH. PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. PATIENT IS NOT CONCURRENTLY OR INTERMITTENTLY TAKING NITRATES, NITRIC OXIDE DONORS OR ANY PDE INHIBITORS (E.G. VIAGRA, CIALIS, DIPYRIDAMOLE).
<b>Required Medical Information</b>	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. DIAGNOSIS OF PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) WHO GROUP 4. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL FOR PAH: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. PREVIOUS TRIAL OF OR CONTRAINDICATION TO A PHOSPHODIESTERASE-5 (PDE-5) INHIBITOR, SUCH AS REVATIO OR ADCIRCA.</p> <p>RENEWAL FOR PAH AND CTEPH: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.</p>

# RITUXIMAB

---

## Products Affected

- Rituxan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NHL, CLL: ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO. RENEWAL: 12 MONTHS. NHL: 1 YEAR. CLL: 6 MO. WG, MPA: 3 MONTH.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS: PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: ORENCIA, XELJANZ, CIMZIA OR ACTEMRA.



# RITUXIMAB SQ

---

## Products Affected

- Rituxan Hycela

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THE PATIENT HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE.

# RUCAPARIB

---

## Products Affected

- Rubraca

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# RUXOLITINIB

---

## Products Affected

- Jakafi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: IMPROVEMENT OR MAINTENANCE OF SYMPTOM IMPROVEMENT SUCH AS A 50% OR GREATER REDUCTION IN TOTAL SYMPTOM SCORE ON THE MODIFIED MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 OR 50% OR GREATER REDUCTION IN PALPABLE SPLEEN LENGTH, OR REDUCTION OF 35% OR GREATER FROM BASELINE SPLEEN VOLUME AFTER 6 MONTHS OF THERAPY.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	

# SAFINAMIDE MESYLATE

---

## Products Affected

- Xadago

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# SARILUMAB

---

## Products Affected

- Kevzara

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PREVIOUS TRIAL OF HUMIRA AND ONE OF THE FOLLOWING PREFERRED AGENTS: ACTEMRA, CIMZIA, ORENCIA, OR XELJANZ.

# SEBELIPASE ALFA

---

## Products Affected

- Kanuma

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	BLOOD TEST OR DRIED BLOOD SPOT TEST INDICATING LOW OR ABSENT LYSOSOMAL ACID LIPASE DEFICIENCY (LAL) ENZYME ACTIVITY, OR A GENETIC TEST INDICATING THE PRESENCE OF ALTERED LIPA GENE(S).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH AN ENDOCRINOLOGIST, HEPATOLOGIST, GASTROENTEROLOGIST, MEDICAL GENETICIST, LIPIDOLOGIST, OR A METABOLIC SPECIALIST.
<b>Coverage Duration</b>	LAL INITIAL 6 OR 12 MONTHS, SEE OTHER CRITERIA. RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY, AS CONFIRMED BY THE PRESENCE OF CLINICAL FEATURES (E.G., HEPATOMEGALY, ELEVATED SERUM TRANSAMINASES, DYSLIPIDEMIA, SPLENOMEGALY) PLUS ANY OF THE FOLLOWING: A BLOOD TEST INDICATING LOW OR ABSENT LEVELS OF LAL ENZYME ACTIVITY, A DRIED BLOOD SPOT TEST INDICATING LOW OR ABSENT LAL ENZYME ACTIVITY, OR A GENETIC TEST INDICATING THE BI-ALLELIC PRESENCE OF ALTERED LIPA GENE(S).</p> <p>RENEWAL:DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING AFTER THE FIRST 6 MONTHS OF LIFE AND NOT CONSIDERED RAPIDLY PROGRESSIVE REQUIRES DOCUMENTED IMPROVEMENT IN ANY ONE OF THE FOLLOWING CLINICAL PARAMETERS ASSOCIATED WITH LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY DURING THE PAST 6 MONTHS: A RELATIVE REDUCTION FROM BASELINE IN ANY ONE OF THE FOLLOWING LIPID LEVELS (LDL-C, NON-HDL-C, OR TRIGLYCERIDES), NORMALIZATION OF ASPARTATE AMINOTRANSFERASE (AST) BASED ON AGE- AND GENDER-SPECIFIC NORMAL RANGES, A DECREASE IN LIVER FAT CONTENT COMPARED TO BASELINE ASSESSED BY ABDOMINAL IMAGING (E.G., MULTI-ECHO GRADIENT ECHO [MEGE] MRI). DIAGNOSIS OF RAPIDLY PROGRESSIVE LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING WITHIN THE FIRST 6 MONTHS OF LIFE: 12 MONTHS. A DIAGNOSIS OF LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY PRESENTING AFTER THE FIRST 6 MONTHS OF LIFE AND NOT CONSIDERED RAPIDLY PROGRESSIVE: INITIAL: 6 MONTHS</p>

# SECUKINUMAB

## Products Affected

- Cosentyx (2 Syringes)
- Cosentyx Pen (2 Pens)

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PLAQUE PSORIASIS (PSO): MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5 PERCENT BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PLAQUE PSORIASIS (PSO): PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 4 MONTHS. RENEWAL: 12 MONTHS FOR ALL DIAGNOSES
<b>Other Criteria</b>	INITIAL: PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA AND ONE CONVENTIONAL THERAPY SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. ANKYLOSING SPONDYLITIS (AS): PREVIOUS TRIAL OF HUMIRA.



# SELEXIPAG

## Products Affected

- Upravi oral tablet 1,000 mcg, 1,200 mcg, 1,400 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg
- Upravi oral tablets, dose pack

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT SHOWS IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

# SILTUXIMAB

---

## Products Affected

- Sylvant

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# SIMEPREVIR

---

## Products Affected

- Olysio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS. FOR ALL GENOTYPE 1A: NS3 80K POLYMORPHISM LAB TEST AT BASELINE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (FOR EXAMPLE HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSa GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSa GUIDANCE. PATIENT MUST NOT BE TAKING ANY OF THE FOLLOWING INTERACTING MEDICATIONS: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ERYTHROMYCIN (DOES NOT INCLUDE TOPICAL FORMULATIONS), CLARITHROMYCIN, TELITHROMYCIN, ITRACONAZOLE, KETOCONAZOLE, POSACONAZOLE, FLUCONAZOLE (DOES NOT INCLUDE TOPICAL FORMULATIONS), VORICONAZOLE, DEXAMETHASONE, CISAPRIDE, CYCLOSPORINE, ROSUVASTATIN DOSE ABOVE 10MG, ATORVASTATIN DOSE ABOVE 40MG, OR ANY OF THE FOLLOWING HIV MEDICATIONS: COBICISTAT-CONTAINING MEDS (E.G., STRIBILD), ANY HIV PROTEASE INHIBITOR (ATAZANAVIR, FOSAMPRENAVIR, LOPINAVIR, INDINAVIR, NELFINAVIR, SAQUINAVIR, OR TIPRANAVIR) RITONAVIR, DARUNAVIR/RITONAVIR, DELAVIRDINE, ETRAVIRINE, NEVIRAPINE, EFAVIRENZ). PATIENT MUST ALSO NOT BE TAKING AMIODARONE IF ON COMBINATION REGIMEN OF SOVALDI AND OLYSIO.</p>

# SOFOSBUVIR

## Products Affected

- Sovaldi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE AND ADDITIONAL CONSIDERATION FOR COVERAGE CONSISTENT WITH FDA LABELING.
<b>Exclusion Criteria</b>	PATIENT WITH END STAGE RENAL DISEASE OR REQUIRES DIALYSIS.
<b>Required Medical Information</b>	FOR ALL GENOTYPE 1 PATIENTS USING OLYSIO AND SOVALDI AND HAVE GENOTYPE 1A: NS3 80K POLYMORPHISM LAB TEST AT BASELINE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE. FOR PATIENTS ON SOVALDI PLUS DAKLINZA REGIMENS THERE WILL BE NO APPROVALS FOR CONCURRENT USE OF ANY OF THESE (CONTRAINDICATED OR NOT RECOMMENDED BY THE MANUFACTURER) MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, OR RIFAMPIN. REQUESTS FOR SOVALDI IN COMBINATION WITH DAKLINZA OR OLYSIO WILL REQUIRE THAT THE PATIENT ALSO MEETS ALL CRITERIA FOR THE RESPECTIVE AGENT USED (DAKLINZA OR OLYSIO).</p>

# SOFOSBUVIR/VELPATASVIR

## Products Affected

- Epclusa

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDS A GUIDANCE.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL.
<b>Age Restrictions</b>	18 YEARS OF AGE AND OLDER.
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDS A GUIDANCE.
<b>Other Criteria</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDS A GUIDANCE. HCV RNA LEVEL WITHIN PAST 6 MONTHS. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED BY THE MANUFACTURER: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANAVIR/RITONAVIR OR TOPOTECAN. PATIENT MUST NOT HAVE SEVERE RENAL IMPAIRMENT, ESRD OR ON HEMODIALYSIS. RIBAVIRIN USE REQUIRED FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS.

# SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

## Products Affected

- Vosevi

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD-IDSA GUIDANCE.
<b>Exclusion Criteria</b>	SEVERE RENAL IMPAIRMENT, ESRD OR ON HEMODIALYSIS. MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (HEPATOLOGIST), OR A SPECIALLY TRAINED GROUP SUCH AS ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES) MODEL.
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. PATIENT IS NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS NOT RECOMMENDED BY THE MANUFACTURER: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR OR TIPRANA VIR/RITONAVIR.



# SOMATROPIN - GROWTH HORMONE

## Products Affected

- Humatrope
- Omnitrope
- Saizen
- Saizen click.easy
- Zomacton

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE WITH CLOSED EPIPHYSES.
<b>Required Medical Information</b>	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: ENDOCRINOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	INITIAL: PREVIOUS TRIAL OF PREFERRED FORMULARY ALTERNATIVES NORDITROPIN AND GENOTROPIN PER FDA INDICATION. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# SOMATROPIN - SEROSTIM

## Products Affected

- Serostim subcutaneous recon soln 4 mg, 5 mg, 6 mg

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	HIV/WASTING: MEETS CRITERIA OF WEIGHT LOSS: 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, OR 7.5% OVER 6 MONTHS, OR 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, OR A BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND A BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, OR BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND A BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, OR BMI LESS THAN 20 KG PER METER SQUARED.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST (SBS), OR INFECTIOUS DISEASE SPECIALIST
<b>Coverage Duration</b>	3 MONTHS
<b>Other Criteria</b>	HIV/WASTING: CURRENTLY ON ANTIRETROVIRAL THERAPY. IF CURRENTLY ON GROWTH HORMONE, PATIENT HAS SHOWN CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT OR IF NOT ON GROWTH HORMONE, PATIENT HAS HAD INADEQUATE RESPONSE TO PREVIOUS THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# SOMATROPIN - ZORBTIVE

---

## Products Affected

- Zorbtive

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST
<b>Coverage Duration</b>	SHORT BOWEL: 4 WEEKS ONCE
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# SOMATROPIN-NORDITROPIN AND GENOTROPIN

## Products Affected

- Genotropin
- Genotropin MiniQuick
- Norditropin FlexPro

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE WITH CLOSED EPIPHYSES.
<b>Required Medical Information</b>	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: ENDOCRINOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT (I.E. INCREASED HEIGHT OR INCREASED GROWTH VELOCITY). THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# SOMATROPIN-NUTROPIN AND NUTROPIN AQ

## Products Affected

- Nutropin AQ Nuspin

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES, GROWTH FAILURE DUE TO CKD IF PATIENT HAS HAD A RENAL TRANSPLANT, OR GROWTH FAILURE WITH CLOSED EPIPHYSES.
<b>Required Medical Information</b>	INDUCTION - PATIENT'S HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. RENEWAL: GROWTH VELOCITY AND/OR TARGET HEIGHT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: ENDOCRINOLOGIST. FOR GROWTH HORMONE FAILURE DUE TO CRI: NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	ALL DIAGNOSES EXCEPT FOR CHRONIC KIDNEY DISEASE (CKD): INITIAL: PREVIOUS TRIAL OF PREFERRED FORMULARY ALTERNATIVES NORDITROPIN AND GENOTROPIN PER FDA INDICATION. RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT (I.E. INCREASED HEIGHT OR INCREASED GROWTH VELOCITY). FOR GROWTH FAILURE SECONDARY TO CKD: PATIENT HAS NOT RECEIVED A RENAL TRANSPLANT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION.

# SONIDEGIB

---

## Products Affected

- Odomzo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# SORAFENIB TOSYLATE

---

## Products Affected

- Nexavar

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# SUNITINIB MALATE

---

## Products Affected

- Sutent

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO GLEEVEC.



# TALIMOGENE

---

## Products Affected

- Imlygic injection suspension 10exp6 (1 million) PFU/mL, 10exp8 (100 million) PFU/mL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	HISTORY OF PRIMARY OR ACQUIRED IMMUNODEFICIENT STATES, LEUKEMIA, LYMPHOMA, OR AIDS. PATIENT IS NOT CURRENTLY RECEIVING IMMUNOSUPPRESSIVE THERAPY.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	IMLYGIC TO BE INJECTED INTO CUTANEOUS, SUBCUTANEOUS, AND OR NODAL LESIONS THAT ARE VISIBLE, PALPABLE, OR DETECTABLE BY ULTRASOUND GUIDANCE. NO CONCURRENT USE WITH PEMBROLIZUMAB, NIVOLUMAB, IPILIMUMAB, DABRAFENIB, TRAMETINIB, VEMURAFENIB, INTERLEUKIN-2, INTERFERON, DACARBAZINE, TEMOZOLOMIDE, PACLITAXEL, CARBOPLATIN, IMATINIB, MELPHALAN, IMIQUIMOD, OR RADIATION THERAPY.

# TASIMELTEON

---

## Products Affected

- Hetlioz

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TEDUGLUTIDE

---

## Products Affected

- Gattex 30-Vial

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS OF AGE AND OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PATIENT IS DEPENDENT ON INTRAVENOUS PARENTERAL NUTRITION DEFINED AS REQUIRING PARENTERAL NUTRITION AT LEAST THREE TIMES PER WEEK.

# TELOTRISTAT

---

## Products Affected

- Xermelo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TEMOZOLOMIDE

---

## Products Affected

- Temodar intravenous

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TERIFLUNOMIDE

---

## Products Affected

- Aubagio

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TERIPARATIDE

## Products Affected

- Forteo

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	24 MONTHS OR MORE OF ANABOLIC THERAPY.
Required Medical Information	ONE OF THE FOLLOWING: (1) HIGH RISK FOR FRACTURES DEFINED AS ONE OF THE FOLLOWING: A) HISTORY OF OSTEOPOROTIC (I.E., FRAGILITY, LOW TRAUMA) FRACTURE(S). B) 2 OR MORE RISK FACTORS FOR FRACTURE (E.G., HISTORY OF MULTIPLE RECENT LOW TRAUMA FRACTURES, BMD T-SCORE LESS THAN OR EQUAL TO -2.5, CORTICOSTEROID USE, OR USE OF GNRH ANALOGS SUCH AS NAFARELIN, ETC.). C) NO PRIOR TREATMENT FOR OSTEOPOROSIS AND FRAX SCORE OF AT LEAST 20% FOR ANY MAJOR FRACTURE OR OF AT LEAST 3% FOR HIP FRACTURE. (2) UNABLE TO USE ORAL THERAPY (I.E., UPPER GASTROINTESTINAL PROBLEMS UNABLE TO TOLERATE ORAL MEDICATION, LOWER GASTROINTESTINAL PROBLEMS UNABLE TO ABSORB ORAL MEDICATIONS, TROUBLE REMEMBERING TO TAKE ORAL MEDICATIONS OR COORDINATING AN ORAL BISPHOSPHONATE WITH OTHER ORAL MEDICATIONS OR THEIR DAILY ROUTINE). (3) ADEQUATE TRIAL OF, INTOLERANCE TO, OR A CONTRAINDICATION TO BISPHOSPHONATES (E.G., ALENDRONATE, RISEDRONATE, IBANDRONATE).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	

# TESTOSTERONE

## Products Affected

- Androderm mg/2.5 gram)
- AndroGel transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)
- AndroGel transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5
- testosterone cypionate
- testosterone enanthate
- testosterone transdermal gel
- testosterone transdermal gel in packet

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ADDITIONAL CONSIDERATION FOR GENDER DYSPHORIA.
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM CONFIRMED BY EITHER: 1) LAB CONFIRMED TOTAL SERUM TESTOSTERONE LEVEL OF LESS THAN 300 NG/DL OR 2) A LOW TOTAL SERUM TESTOSTERONE LEVEL AS INDICATED BY A LAB RESULT WITH A REFERENCE RANGE OBTAINED WITHIN 90 DAYS, OR 3) A FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 PG/ML.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	LIFETIME OF MEMBERSHIP IN PLAN
Other Criteria	



# TETRABENAZINE

---

## Products Affected

- tetrabenazine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NEUROLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# THALIDOMIDE

---

## Products Affected

- Thalomid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TOCILIZUMAB IV

## Products Affected

- Actemra

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RENEWAL FOR RA, PJIA, OR SJIA: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)/POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA)/ SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST
<b>Coverage Duration</b>	INITIAL: RA: 6 MONTHS. PJIA: 5 MOS. SJIA: 12 MOS. CRS: 1 MO. RENEWAL: 12 MOS FOR RA, PJIA, OR SJIA
<b>Other Criteria</b>	INITIAL: MODERATE TO SEVERE RA AND PJIA: PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE. INITIAL SJIA: PREVIOUS TRIAL WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

# TOCILIZUMAB SQ

---

## Products Affected

- Actemra

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	RA RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA INITIAL: 6 MONTHS. RA RENEWAL: 12 MONTHS. GIANT CELL ARTERITIS: 12 MONTHS
<b>Other Criteria</b>	RA INITIAL : PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) AGENT SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

# TOFACITINIB

## Products Affected

- Xeljanz
- Xeljanz XR

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	RENEWAL: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS: PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	RA: INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS: PREVIOUS TRIAL OF HUMIRA AND ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) SUCH AS METHOTREXATE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, OR SULFASALAZINE.

# TOPICAL TRETINOIN

---

## Products Affected

- tretinoin topical cream
- tretinoin topical gel 0.01 %, 0.025 %

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	WRINKLES, PHOTOAGING, MELASMA.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TRABECTEDIN

---

## Products Affected

- Yondelis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# TRAMETINIB DIMETHYL SULFOXIDE

---

## Products Affected

- Mekinist oral tablet 0.5 mg, 2 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	



# TRASTUZUMAB

---

## Products Affected

- Herceptin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	BREAST CANCER, METASTATIC BREAST CANCER, GASTRIC CANCER: HER2 POSITIVE
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	B VS D COVERAGE CONSIDERATION.

# TREPROSTINIL DIOLAMINE

## Products Affected

- Orenitram

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	PATIENT DOES NOT HAVE SEVERE HEPATIC IMPAIRMENT.
Required Medical Information	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL AND RENEWAL: 12 MONTHS
Other Criteria	INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. PREVIOUS OR CURRENT TREATMENT WITH ONE OF THE FOLLOWING AGENTS: A FORMULARY PHOSPHODIESTERASE-5 INHIBITOR (E.G., SILDENAFIL [GENERIC FOR REVATIO] OR ADCIRCA [TADALAFIL]) OR AN ENDOTHELIN RECEPTOR ANTAGONIST (E.G., TRACLEER [BOSENTAN], LETAIRIS [AMBRISENTAN], OR OPSUMIT [MACITENTAN]). TRIAL OF A FORMULARY PHOSPHODIESTERASE-5 INHIBITOR OR ENDOTHELIN RECEPTOR ANTAGONIST IS NOT REQUIRED IF THE PATIENT WAS PREVIOUSLY STABLE ON ORENITRAM. RENEWAL: PATIENT SHOWS IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

# TREPROSTINIL INHALED

## Products Affected

- Tyvaso

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION. PATIENT HAS NYHA-WHO FUNCTIONAL CLASS III-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS
<b>Other Criteria</b>	THIS DRUG MAYBE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. NEBULIZER THERAPY IS COVERED UNDER PART B FOR PATIENTS WHO ARE USING THE MEDICATION VIA A NEBULIZER IN THEIR OWN HOME. THOSE WHO ARE NOT USING IT IN THEIR HOME WILL BE COVERED UNDER PART D. INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.

# TREPROSTINIL SODIUM INJECTABLE

## Products Affected

- Remodulin

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	COVERED UNDER LOCAL COVERAGE POLICY OF APPLICABLE MEDICARE DMERC.
<b>Required Medical Information</b>	FORMULARY DRUG ADMINISTERED IN A LONG TERM CARE FACILITY TO A PATIENT WHOSE PART A COVERAGE HAS EXPIRED OR FORMULARY DRUG NOT ADMINISTERED VIA AN IMPLANTABLE PUMP OR AN EXTERNAL PUMP OR DRUG ADMINISTERED VIA AN IMPLANTABLE PUMP/AN EXTERNAL PUMP. DOCUMENTED CONFIRMATORY PULMONARY ARTERIAL HYPERTENSION (PAH) DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST
<b>Coverage Duration</b>	INITIAL AND RENEWAL: 12 MONTHS

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: MEAN PULMONARY ARTERY PRESSURE (PAP) OF AT LEAST 25 MMHG OR GREATER, PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 3 WOOD UNITS. CONTINUATION OF CURRENT REMODULIN THERAPY: PATIENT MUST HAVE NYHA/WHO FC II-IV SYMPTOMS. NEW REQUESTS FOR REMODULIN THERAPY: PATIENT MUST HAVE NYHA/WHO FC III-IV SYMPTOMS. NEW REQUESTS FOR REMODULIN THERAPY FOR PATIENTS WITH NYHA/WHO FC II SYMPTOMS REQUIRES A TRIAL OF OR CONTRAINDICATION TO A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5) (E.G., REVATIO, ADCIRCA) OR AN ENDOTHELIN RECEPTOR ANTAGONIST (ERA) (E.G., LETAIRIS, OPSUMIT, TRACLEER). RENEWAL: PATIENT SHOW IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR PATIENT HAS A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/ IMPROVED WHO FUNCTIONAL CLASS.</p>

# TRIENTINE

## Products Affected

- Syprine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	KNOWN FAMILY HISTORY OF WILSON'S DISEASE OR PHYSICAL EXAMINATION CONSISTENT WITH WILSON'S DISEASE. PLASMA COPPER-PROTEIN CERULOPLASMIN LESS THAN 20 MG/DL. LIVER BIOPSY POSITIVE FOR AN ABNORMALLY HIGH CONCENTRATION OF COPPER (GREATER THAN 250 MCG/G DRY WEIGHT) OR THE PRESENCE OF KAYSER-FLEISCHER RINGS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A HEPATOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	PREVIOUS TRIAL OF OR CONTRAINDICATION TO PENICILLAMINE (DEPEN).

# TRIFLURIDINE/TIPIRACIL

---

## Products Affected

- Lonsurf oral tablet 15-6.14 mg, 20-8.19 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# URIDINE TRIACETATE

## Products Affected

- Xuriden

PA Criteria	Criteria Details
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: DIAGNOSIS CONFIRMED BY 1) GENETIC MUTATION OF URIDINE MONOPHOSPHATE SYNTHASE (UMPS) GENE AND 2) ELEVATED URINE OROTIC ACID PER AGE-SPECIFIC REFERENCE RANGE. RENEWAL: IMPROVEMENT FROM BASELINE OR STABILIZATION OF AGE DEPENDENT HEMATOLOGIC PARAMETERS (E.G., NEUTROPHIL COUNT, NEUTROPHIL PERCENT, WBC COUNT, MEAN CORPUSCULAR VOLUME)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	



# USTEKINUMAB

## Products Affected

- Stelara subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS: MODERATE TO SEVERE PLAQUE PSORIASIS INVOLVING GREATER THAN OR EQUAL TO 5% BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, OR GENITAL AREA. RENEWAL FOR PSORIATIC ARTHRITIS OR PLAQUE PSORIASIS: PHYSICIAN ATTESTATION OF IMPROVEMENT.
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH: PSORIATIC ARTHRITIS: DERMATOLOGIST OR RHEUMATOLOGIST. PLAQUE PSORIASIS: DERMATOLOGIST. CROHN'S DISEASE: GASTROENTEROLOGIST.
Coverage Duration	INITIAL: PSA, PSO, CD: 4 MONTHS. CD WITH PREVIOUS DOSE IV: 2 MONTHS. RENEW ALL: 12 MO
Other Criteria	INITIAL: PSORIATIC ARTHRITIS (PSA): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: CIMZIA, OTEZLA, OR COSENTYX. PLAQUE PSORIASIS (PSO): PREVIOUS TRIAL OF HUMIRA FOLLOWED BY ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX OR OTEZLA. CROHN'S DISEASE (CD): PREVIOUS TRIAL OF OR CONTRAINDICATION TO PREFERRED TNF INHIBITORS: HUMIRA FOLLOWED BY CIMZIA.

# USTEKINUMAB IV

---

## Products Affected

- Stelara intravenous

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	2 MONTHS
<b>Other Criteria</b>	PREVIOUS TRIAL OF OR CONTRAINDICATION TO THE PREFERRED TNF INHIBITORS: HUMIRA FOLLOWED BY CIMZIA. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

# VALBENAZINE TOSYLATE

---

## Products Affected

- Ingrezza oral capsule 40 mg, 80 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PATIENT HAS BEEN STABLE ON ANTIPSYCHOTIC MEDICATIONS OR METOCLOPRAMIDE PER PHYSICIAN ATTESTATION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR GIVEN IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# VANDETANIB

---

## Products Affected

- Caprelsa oral tablet 100 mg, 300 mg

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# VEMURAFENIB

---

## Products Affected

- Zelboraf

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	BRAFV600E MUTATION
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# VENETOCLAX

---

## Products Affected

- Venclexta oral tablet 10 mg, 100 mg, 50 mg
- Venclexta Starting Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

# VISMODEGIB

---

## Products Affected

- Erivedge

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	

## INDEX

12 HOUR RELIEF TABLET .....	17	ADVOCATE 30G LANCETS TWIST TOP .....	109
1ST TIER COMFORTOUCH 28G LANCT .....	109	ADVOCATE REDI-CODE TEST STRIP .....	109
1ST TIER COMFORTOUCH 30G LANCT .....	109	ADVOCATE REDI-CODE+ TEST STRIP NO CODING .....	109
25DPH-7.5PEH LIQUID .....	17	ADVOCATE TEST STRIP .....	109
ACCU-CHEK AVIVA PLUS TEST STRP .....	109	Afinitor Disperz .....	96
ACCU-CHEK COMPACT PLUS STRIPS 3 TEST DRUMS .....	109	Afinitor oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg .....	96
ACCU-CHEK COMPACT STRIPS MEDICARE-M-CAID ONLY .....	109	AGAMATRIX AMP TEST STRIPS ....	109
ACCU-CHEK FASTCLIX LANCETS	109	ALA-HIST IR 2 MG TABLET .....	17
ACCU-CHEK GUIDE TEST STRIP ...	109	ALA-HIST PE TABLET .....	17
ACCU-CHEK MULTICLIX LANCETS .....	109	ALAVERT 10 MG ODT .....	17
ACCU-CHEK SAFE-T-PRO 23G LANCT .....	109	Alecensa .....	11
ACCU-CHEK SAFE-T-PRO PLUS 23G .....	109	ALER-CAPS 25 MG CAPSULE .....	20
ACCU-CHEK SMARTVIEW TEST STRIP .....	109	ALER-TAB 25 MG TABLET .....	20
ACCU-CHEK SOFTCLIX LANCETS	109	Aliqopa .....	52
ACCUTREND GLUCOSE TEST STRIP .....	109	ALKA-SELTZER PLUS ALLERGY TAB .....	20
ACETAMINOPHEN 160 MG/5 ML ELX .....	7	ALLER-CHLOR 2 MG/5 ML SYRUP ..	17
Actemra .....	266, 267	ALLER-CHLOR 4 MG TABLET .....	17
ACTI-LANCE LITE 28G LANCETS ..	109	ALLERGY 4 MG TABLET .....	17
ACTI-LANCE SPECIAL 17G LANCETS .....	109	ALLERHIST-1 1.34 MG TABLET .....	17
ACTI-LANCE UNIVERS 23G LANCETS .....	109	ALTERNATE SITE 26G LANCETS RECAPABLE .....	109
Adcirca .....	207	Alunbrig .....	40
Adempas .....	229	AMBI 60PSE-4CPM TABLET .....	17
ADVANCED TRAVEL 28G LANCETS 28G,SINGLE-USE,STRL ..	109	amitriptyline .....	138
ADVANCED TRAVEL 30G LANCETS .....	109	amoxapine .....	138
ADVOCATE 26G LANCETS 26 G,STERILE .....	109	Ampyra .....	58
ADVOCATE 26G LANCETS STERILE .....	109	Anadrol-50 .....	201
		Androderm .....	263
		AndroGel transdermal gel in metered- dose pump 20.25 mg/1.25 gram (1.62 %)	263
		AndroGel transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram) .....	263
		ANTIHISTAMINE 25 MG CAPSULE ..	20
		APRODINE TABLET .....	17
		armodafinil .....	180
		Ascomp with Codeine .....	122
		ASSURE 4 TEST STRIPS .....	109



ASSURE COMFORT 30G LANCETS	109	BLOOD GLUCOSE TEST STRIP NO	
ASSURE HAEMOLANCE PLUS 18G	109	CODING	109
ASSURE HAEMOLANCE PLUS 21G	109	BLOOD GLUCOSE TEST STRIPS	109
ASSURE HAEMOLANCE PLUS 25G	109	BLOOD LANCETS 30G EASY TWIST	
ASSURE HAEMOLANCE PLUS 28G	109		109
ASSURE LANCE 25G LANCETS	109	Bosulif oral tablet 100 mg, 500 mg	39
ASSURE LANCE 28G LANCETS	109	BROTAPP LIQUID	17
ASSURE LANCE PLUS 21G		BULLSEYE MINI SAFETY 21G	109
LANCETS	109	BULLSEYE MINI SAFETY 25G	
ASSURE LANCE PLUS 25G		LANCT	109
LANCETS	109	Butalbital Compound W/Codeine	122
ASSURE LANCE PLUS 30G		butalbital-acetaminop-caf-cod	122
LANCETS	109	butalbital-acetaminophen oral tablet 50-	
ASSURE PLATINUM TEST STRIPS	109	325 mg	122
ASSURE PRISM MULTI TEST		butalbital-acetaminophen-caff oral	
STRIPS	109	capsule 50-325-40 mg	122
Aubagio	261	butalbital-acetaminophen-caff oral	
Austedo oral tablet 12 mg, 6 mg, 9 mg	68	tablet 50-325-40 mg	122
Avastin	35	butalbital-aspirin-caffeine	122
Avonex (with albumin)	154	Cabometyx oral tablet 20 mg, 40 mg, 60	
Avonex intramuscular pen injector kit	154	mg	44
Avonex intramuscular syringe kit	154	Calquence	6
BANOPHEN 25 MG CAPSULE	20	Capacet	122
BANOPHEN 25 MG TABLET	20	Caprelsa oral tablet 100 mg, 300 mg	283
BANOPHEN 50 MG CAPSULE	20	CAREONE ULTRA THIN LANCET	109
BANOPHEN ALLERGY 12.5 MG/5		CARESENS N TEST STRIPS NO	
ML A/F	20	CODING	109
Bavencio	29	CARESENS ULTRA THIN 30G	
Baxdela oral	66	LANCET	109
BD MICROTAINER 21G LANCETS	109	CARETOUCH TWIST 28G LANCET	109
BD MICROTAINER 30G LANCETS	109	CARETOUCH TWIST 30G LANCET	109
BD ULTRA-FINE 33G LANCETS	109	carisoprodol	128
BD ULTRA-FINE II 30G LANCETS	109	Cerdelga	80
Beleodaq	33	CETIRIZINE HCL 1 MG/ML SOLN	
BENADRYL ALLERGY 25 MG		CHILDREN, S/F, GRAPE (OTC)	17
ULTRATB ULTRATAB	20	CETIRIZINE HCL 10 MG CHEW	
Bendeka	34	TAB CHILDREN'S, OUTER, U-D	17
Benlysta intravenous	32	CETIRIZINE HCL 10 MG TABLET	17
Benlysta subcutaneous	32	CETIRIZINE HCL 5 MG TABLET	17
benztropine oral	119	CHILD ACETAMINOPHEN 80	
Besponsa	152	MG/2.5 ML ORAL SYRINGE 50'S, U-	
Betaseron subcutaneous kit	155	D, ORAL SYR	7
bexarotene	36	CHILD ALLEGRA ALLERGY 30	
Blinicyto intravenous kit	37	MG/5 ML SUSPENSION	17

CHILD CETIRIZINE 5 MG CHEW TAB.....	17	COAGUCHEK LANCETS.....	109
CHILD DOMETUSS-DA LIQUID.....	17	Cold-Allergy-Sinus.....	17
CHILD LORATADINE 5 MG/5 ML SYR GRAPE, S/F.....	17	CombiPatch.....	125
CHILD PAIN-FEVER 160 MG/5 ML.....	7	Cometriq.....	43
CHILD TRIAMINIC COLD & ALLERGY.....	17	COMFORT EZ SAFETY 21G LANCETS.....	109
CHILD WAL-ITIN 5 MG/5 ML SOLN.....	17	COMFORT EZ SAFETY 23G LANCETS.....	109
CHILD WAL-TAP COLD-ALLERGY ELX.....	17	COMFORT EZ SAFETY 28G LANCETS.....	109
CHILD WAL-ZYR 1 MG/ML SOLUTION CHERRY.....	17	COMFORT LANCETS.....	109
CHILDREN'S COLD & ALLERGY ELXR A/F.....	17	COMPOZ 25 MG GELCAP.....	20
CHILDREN'S SILFEDRINE LIQ.....	17	CONEX SOLUTION.....	17
CHILDREN'S WAL-FEX 30 MG/5 ML.....	17	CONEX TABLET.....	17
CHILD'S ALLER-TEC 1 MG/ML SOLN.....	17	CONTOUR NEXT STRIPS.....	109
CHILD'S BENADRYL 12.5 MG/5 ML.....	20	CONTOUR TEST STRIPS.....	109
CHILDS SUDAFED 15 MG/5 ML LIQ NON-DROWSY,A/F,S/F.....	17	COOL GLUCOSE TEST STRIP.....	109
CHILD'S WAL-ZYR 10 MG CHEW TAB.....	17	Copaxone subcutaneous syringe 40 mg/mL.....	106
CHLORHIST 4 MG TABLET.....	17	Corlanor.....	157
CHLORPHENIRAMINE ER 12 MG TAB.....	17	Cosentyx (2 Syringes).....	239
chlorzoxazone oral tablet 500 mg.....	128	Cosentyx Pen (2 Pens).....	239
CHOICEDM CLARUS TEST STRIPS.....	109	Cotellic.....	51
Cimzia.....	49	Cuprimine.....	212
Cimzia Powder for Reconst.....	49	CVS ADVANCED GLUCOSE TEST STR.....	109
Cinqair.....	226	CVS ALLERGY 25 MG TABLET.....	20
Cinryze.....	42	CVS ALLERGY-D TABLET.....	17
CLEVER CHEK ULTRA THIN 30G..	109	CVS CHILD ALLERGY 10 MG CHW TB 24 HR,INDOOR/OUTDOOR.....	17
CLEVER CHOICE MICRO TEST STRIP.....	109	CVS CHILD PAIN RLF 160 MG/5 ML CHILDREN'S, A/F.....	7
CLEVER CHOICE PRO TEST STRIP.....	109	CVS COLD & COUGH NIGHTTIME LIQ.....	17
CLEVER CHOICE TALK TEST STRIPS.....	109	CVS MOTION SICKNESS RELIEF TAB CHEWABLE TABLET.....	17
CLEVER CHOICE TEST STRIPS AUTO-CODE.....	109	CVS NOSE DROPS.....	17
CLEVER CHOICE VOICE+ TST STRIP AUTO-CODE.....	109	CVS PRENATAL GUMMY VITAMINS.....	219
clomipramine.....	138	CVS PRENATAL MULTI-DHA SOFTGEL.....	219
		CVS PRENATAL VITAMIN TABLET .....	219
		CVS THIN 26G LANCETS.....	109
		CVS ULTRA THIN 30G LANCETS...	109

CVS WOMEN'S PRENATAL + DHA	219	Dupixent	75
cyclobenzaprine oral tablet 10 mg, 5 mg	128	EASY COMFORT 30G LANCETS	
cyproheptadine	129	30G,TWIST TOP,STRL	109
Cyramza	224	EASY GLUCO G2 TEST STRIP	109
DAILY PRENATAL COMBO PACK	219	EASY PLUS GLUCOSE TEST STRIP	109
DAILYHIST-1 1.34 MG TABLET	17	EASY PLUS II TEST STRIPS	109
Daklinza	55	EASY STEP GLUCOSE TEST STRIPS	
DALLERGY 1-5 MG TABLET	17	.....	109
Daraprim	221	EASY TALK GLUCOSE TEST STRIP	
DARIO BLOOD GLUCOSE TEST STRIP	109	.....	109
Darzalex	59	EASY TOUCH 28G LANCETS	
DAYHIST ALLERGY 1.34 MG TABLET 12 HR RELIEF	17	28G,PULL TOP,STERILE	109
DAYHIST TABLET	17	EASY TOUCH GLUCOSE TEST STRIP	109
deferoxamine	63	EASY TOUCH SAFETY 21G LANCETS	109
Depen Titratabs	213	EASY TOUCH SAFETY 23G LANCETS	109
desipramine	138	EASY TOUCH SAFETY 26G LANCETS	109
DIATRUE PLUS TEST STRIP	109	EASY TOUCH TWIST 28G LANCETS	109
diclofenac sodium topical gel 3 %	71	EASY TOUCH TWIST 30G LANCETS	109
Digitek oral tablet 125 mcg, 250 mcg	124	EASY TOUCH TWIST 32G LANCETS	109
Digox oral tablet 125 mcg, 250 mcg	124	EASY TOUCH TWIST 33G LANCETS	109
DIGOXIN 0.25 MG/ML SYRINGE	124	EASY TRAK GLUCOSE TEST STRIP	109
digoxin injection solution	124	.....	109
digoxin oral solution 50 mcg/mL	124	EASY TWIST & CAP 28G LANCETS	109
digoxin oral tablet 125 mcg, 250 mcg	124	EASYGLUCO PLUS TEST STRIPS	109
DIMAPHEN ELIXIR A/F, GRAPE, GLUTEN-F	17	EASYGLUCO TEST STRIPS	109
DIMETAPP COLD & CONGEST LIQUID	17	EASYMAX 15 GLUCOSE TEST STRIP	109
DIPHEDRYL 12.5 MG/5 ML ELIXIR	20	EASYMAX GLUCOSE TEST STRIPS	
DIPHENHIST 12.5 MG/5 ML SOLN	20	MEDICAL BENEFIT USE	109
DIPHENHIST 25 MG CAPSULE	20	ED A-HIST LIQUID (OTC)	17
DIPHENHIST 25 MG CAPTAB CAPTAB	20	ED CHLORPED DROPS	17
DIPHENHYDRAMINE 25 MG CAPSULE (OTC)	20	ED CHLORPED JR SYRUP	17
diphenhydramine HCl oral elixir	130	ED-A-HIST 4 MG-10 MG TABLET	17
diphenoxylate-atropine	131	ELEMENT COMPACT TEST STRIPS	109
doxepin oral	138	ELEMENT TEST STRIPS	109
DRAMAMINE LESS DROWSY 25 MG TB	17	EMBRACE 30G LANCETS	109
dronabinol	46	EMBRACE EVO TEST STRIPS	109
DROPLET 30G LANCETS	109		
Duavee	125		

EMBRACE PRO TEST STRIPS.....	109	E-ZJECT COLOR 33G LANCETS.....	109
EMBRACE TEST STRIPS.....	109	E-ZJECT SUPER THIN 30G	
Emflaza oral suspension.....	64	LANCETS SUPER THIN.....	109
Emflaza oral tablet 18 mg, 30 mg, 36 mg,		E-ZJECT THIN LANCETS 26	
6 mg.....	64	GAUGE.....	109
Empliciti.....	82	Farydak.....	204
Enbrel.....	93	fentanyl citrate.....	101
Enbrel SureClick.....	93	Ferriprox.....	62
Endari.....	165	FEXOFENADINE HCL 180 MG	
Epclusa.....	246	TABLET 24 HOUR, NON-DROWSY	
EPOGEN 10,000 UNITS/ML VIAL		(OTC).....	17
SDV, P/F, OUTER.....	89	FEXOFENADINE HCL 30 MG/5 ML..	17
Epogen injection solution 2,000 unit/mL,		FEXOFENADINE HCL 60 MG	
20,000 unit/2 mL, 20,000 unit/mL, 3,000		TABLET INDOOR/OUTDOOR (OTC)	17
unit/mL, 4,000 unit/mL.....	89	FIFTY50 GLUCOSE TEST STRIP.....	109
epoprostenol (glycine).....	87	FIFTY50 SAFETY SEAL 30G	
EQ ALLERGY & SINUS RELIEF		LANCET.....	109
TAB.....	17	FIFTY50 SAFETY SEAL 32G	
EQL ALLERGY RELIEF 10 MG ODT		LANCET.....	109
NON-DROWSY.....	17	FINE 30 UNIVERSAL 30G LANCETS	
Erivedge.....	286	.....	109
Esbriet oral capsule.....	215	FINGERSTIX LANCETS.....	109
Esbriet oral tablet 267 mg, 801 mg.....	215	Flector.....	70
estradiol oral.....	125	FOLIC ACID 400 MCG TABLET	
estradiol transdermal patch semiweekly.	125	S/F,P/F,LACTOSE-FREE.....	103
estradiol transdermal patch weekly.....	125	FORA 30G LANCETS TWIST	
estradiol-norethindrone acet.....	125	OFF,SINGLE USE.....	109
estropipate.....	125	FORA BLOOD GLUCOSE TEST	
eszopiclone.....	127	STRIP.....	109
EVENCARE G2 TEST STRIP.....	109	FORA D15G GLUCOSE TEST	
EVENCARE G3 TEST STRIP.....	109	STRIPS.....	109
EVENCARE GLUCOSE TST STRIPS	109	FORA D20 GLUCOSE TEST STRIPS	109
EVENCARE MINI GLUCOSE TEST		FORA D40-G31 TEST STRIPS.....	109
STR.....	109	FORA G20 GLUCOSE TEST STRIPS	109
EVOLUTION TEST STRIPS.....	109	FORA G30A GLUCOSE TEST STRIP	109
Exjade.....	61	FORA GD50 TEST STRIPS.....	109
Exondys 51.....	95	FORA TN'G VOICE TEST STRIPS....	109
EXPECTA PRENATAL COMBO		FORA V10 GLUCOSE TEST STRIP...	109
PACK.....	219	FORA V10-V12-D10-D20 STRIPS.....	109
Extavia subcutaneous kit.....	155	FORA V12 GLUCOSE TEST STRIP...	109
E-Z JECT LANCETS.....	109	FORA V20 GLUCOSE TEST STRIPS.	109
EZ SMART 28G LANCETS.....	109	FORA V30A GLUCOSE TEST STRIP	109
EZ SMART PLUS TEST STRIPS.....	109	FORACARE 30G LANCETS.....	109
EZ SMART TEST STRIPS.....	109	FORACARE GD20 TEST STRIPS.....	109
E-ZJECT COLOR 32G LANCETS.....	109		

FORACARE GD40 GLUCOSE STRIPS.....	109	glyburide.....	126
Forteo.....	262	glyburide micronized.....	126
FORTISCARE GLUCOSE TEST STRIPS.....	109	glyburide-metformin.....	126
FREESTYLE 28G LANCETS.....	109	GMATE 30G LANCETS.....	109
FREESTYLE INSULINX TEST STRIP NO CODE.....	109	GMATE TEST STRIPS.....	109
FREESTYLE INSULINX TEST STRIPS.....	109	GNP UNIVERSAL 1 STANDARD 21G.....	109
FREESTYLE LITE TEST STRIP.....	109	GNP UNIVERSAL 1 SUPER THIN 30G.....	109
FREESTYLE LITE TEST STRIPS.....	109	Gocovri oral capsule,extended release 24hr 137 mg, 68.5 mg.....	15
FREESTYLE PREC NEO TEST STRIPS.....	109	GS BLOOD GLUCOSE TEST STRIP PREMIUM, NO CODE.....	109
FREESTYLE TEST STRIPS.....	109	guanfacine oral tablet.....	123
FREESTYLE UNISTIK 2 LANCETS.....	109	Haegarda.....	42
Gattex 30-Vial.....	258	Harvoni.....	162
Gazyva.....	190	HEALTHPRO GLUCOSE TEST STRIPS.....	109
GE100 BLOOD GLUCOSE TEST STRIP 2 VIALS X 25 STRIPS.....	109	HEALTHY ACCENTS UNILET 30G.....	109
Genotropin.....	251	Herceptin.....	272
Genotropin MiniQuick.....	251	Hetlioz.....	257
GENSTRIP GLUCOSE TEST STRIP.....	109	HISTEX-PE SYRUP.....	17
GENULTIMATE TEST STRIP.....	109	HM Z-SLEEP 25 MG SOFTGEL.....	20
GERI-DRYL 12.5 MG/5 ML LIQUID.....	20	Humatrope.....	248
Gilenya.....	102	Humira.....	8
Gilotrif.....	10	Humira Pediatric Crohn's Start.....	8
glatiramer subcutaneous syringe 20 mg/mL, 40 mg/mL.....	106	Humira Pen.....	8
Glatopa.....	106	Humira Pen Crohn's-UC-HS Start.....	8
GLUCO NAVII GLUCOSE TEST STRIP.....	109	Humira Pen Psoriasis-Uveitis.....	8
GLUCOCARD 01 SENSOR PLUS STRIP.....	109	hydroxyprogesterone caproate.....	141
GLUCOCARD EXPRESSION TEST STRP.....	109	hydroxyzine HCl intramuscular.....	132
GLUCOCARD SHINE TEST STRIPS.....	109	hydroxyzine HCl oral solution 10 mg/5 mL.....	132
GLUCOCARD VITAL SENSOR STRIP.....	109	hydroxyzine HCl oral tablet.....	132
GLUCOCARD VITAL TEST STRIPS.....	109	hydroxyzine pamoate.....	132
GLUCOCOM 28G LANCETS.....	109	Ibrance.....	202
GLUCOCOM 30G LANCETS.....	109	Iclusig oral tablet 15 mg, 45 mg.....	217
GLUCOCOM 33G LANCETS.....	109	Idhifa.....	84
GLUCOCOM GLUCOSE TEST STRIP.....	109	Ilaris (PF).....	45
		imatinib oral tablet 100 mg, 400 mg.....	144
		Imbruvica.....	142
		Imfinzi.....	76
		imipramine HCl.....	138
		imipramine pamoate.....	138
		imiquimod.....	145

Imlygic injection suspension 10exp6 (1 million) PFU/mL, 10exp8 (100 million) PFU/mL.....	256	KRO CHILD NITE TIME COLD & CGH.....	17
Impavido.....	176	KRO PREMIUM BLOOD GLUCOSE TEST NO CODING,PREMIUM.....	109
INCONTROL SUPER THIN 30G LANCET.....	109	KRO PRENATAL VITAMINS TABLET.....	219
INCONTROL ULTRA THIN 28G LANCET.....	109	KRO UNIVERSAL 1 THIN 26G LANCET.....	109
indomethacin oral capsule 25 mg, 50 mg	133	KROGER SUPER THIN LANCETS..	109
indomethacin oral capsule, extended release.....	133	Kynamro.....	177
INFANT PAIN RELV 80 MG/0.8 ML A/F, GLUTEN-FREE.....	7	Kyprolis.....	47
INFANT'S PAIN RELIEF SUSP DROP.....	7	LANCETS 33G.....	109
INFINITY TEST STRIPS.....	109	LANCETS THIN 23G.....	109
Inflectra.....	150	LANCETS ULTRA THIN 26G.....	109
Ingrezza oral capsule 40 mg, 80 mg.....	282	Lanoxin oral tablet 187.5 mcg, 62.5 mcg	124
INJECT EASE 28G LANCETS.....	109	Lartruvo.....	193
INJECT EASE 30G LANCETS.....	109	Lazanda.....	100
Inlyta oral tablet 1 mg, 5 mg.....	30	Lemtrada.....	12
Intron A injection.....	153	Lenvima.....	164
INVACARE 30G LANCETS.....	109	Letairis.....	85
Iprivask.....	67	LIBERTY TEST STRIPS BLOOD GLUCOSE.....	109
Iressa.....	104	lidocaine topical adhesive patch,medicated.....	166
Jadenu.....	61	lidocaine topical ointment.....	166
Jadenu Sprinkle.....	61	LITE TOUCH 30G LANCETS.....	109
Jakafi.....	234	LITE TOUCH 33G LANCETS.....	109
Juxtapid oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 5 mg, 60 mg.....	167	LITTLE REMEDIES FEVER 160 MG/5 A/F,D/F, GLUTEN-FREE.....	7
Kalydeco.....	158, 159	LOHIST-D LIQUID.....	17
Kanuma.....	237	LOMAIRA 8 MG TABLET.....	22
ketorolac oral.....	134	LONGS THIN LANCETS 26G 26G....	109
Keveyis.....	69	Lonsurf oral tablet 15-6.14 mg, 20-8.19 mg.....	278
Kevzara.....	236	Lopreeza.....	125
Keytruda intravenous recon soln.....	211	LORATADINE 10 MG SOFTGEL.....	20
Keytruda intravenous solution.....	211	LORATADINE 10 MG TABLET.....	17
Kineret.....	16	Lynparza oral capsule.....	192
Kisqali.....	227	Lynparza oral tablet.....	192
Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 1)-2.5 mg, 400 mg/day(200 mg x 2)-2.5 mg, 600 mg/day(200 mg x 3)-2.5 mg.....	227	MAPAP 160 MG/5 ML LIQUID.....	7
Korlym.....	175	MAPAP 160 MG/5 ML SUSPENSION....	7
KPN TABLET.....	219	Mavyret.....	107
		MECLIZINE 12.5 MG CAPLET CAPLET (OTC).....	17
		MECLIZINE 25 MG TABLET (OTC)...	17

meclizine oral tablet 12.5 mg, 25 mg.....	135	Northera.....	74
MEDI-MECLIZINE 25 MG TABLET		nortriptyline.....	138
OUTER, F/C.....	17	NOVA MAX GLUCOSE TEST STRIP	109
MEDI-PHEDRINE 30 MG TABLET....	17	NOVA SAFETY 23G LANCETS.....	109
MEDLANCE PLUS 21G LANCETS		NOVA SAFETY 28G LANCETS.....	109
UNIVERSAL.....	109	NOVA SUREFLEX THIN LANCETS	109
MEDLANCE PLUS 30G LANCETS		Nucala.....	171
SUPERLITE, 1.2MM.....	109	Nuplazid.....	214
MEDLANCE PLUS LITE 25G		Nutropin AQ Nuspin.....	252
LANCETS STERILE.....	109	NYTOL 25 MG QUICKCAPS	
megestrol oral suspension 400 mg/10 mL		CAPLET CAPLET.....	20
(40 mg/mL).....	136	Ocaliva.....	189
megestrol oral tablet.....	136	Ocrevus.....	191
Mekinist oral tablet 0.5 mg, 2 mg.....	271	Odomzo.....	253
Menest oral tablet 0.3 mg, 0.625 mg,		Ofev.....	185
1.25 mg.....	125	Olysio.....	242
methocarbamol oral.....	128	Omnitrope.....	248
MICRO THIN 33G LANCETS		ON CALL 30G LANCET.....	109
UNIVERSAL 1.....	109	ON CALL EXPRESS TEST STRIP....	109
MICRODOT TEST STRIPS.....	109	ON CALL PLUS 30G LANCET.....	109
MICRODOT XTRA TEST STRIPS.....	109	ON CALL PLUS TEST STRIP.....	109
MICROLET LANCETS.....	109	ON CALL VIVID TEST STRIP.....	109
Mimvey.....	125	Oncaspar.....	27
Mimvey Lo.....	125	ONE A DAY PRENATAL DHA	
Mircera injection syringe 100 mcg/0.3		PACK 30 LIQ GELS,30 TABS.....	219
mL, 200 mcg/0.3 mL, 50 mcg/0.3 mL, 75		ONE TOUCH DELICA 33G	
mcg/0.3 mL.....	92	LANCETS.....	109
MONOLET 21G LANCETS.....	109	ONE-A-DAY PRENATAL 1 DHA	
MONOLET THIN 28G LANCETS.....	109	SFGL.....	219
MYGLUCOHEALTH 30G LANCETS	109	ONETOUCH DELICA 30G	
MYGLUCOHEALTH TEST STRIPS..	109	LANCETS.....	109
Mylotarg.....	105	ONETOUCH DELICA 33G	
NASAL DECONGEST-ANTI HIST		LANCETS.....	109
TAB.....	17	ONETOUCH SURESOFT LANCING	
NASAL-SINUS DECONGEST TAB....	17	DEV DEVICE & 18G LANCETS.....	109
Natpara.....	205	ONETOUCH ULTRA TEST STRIPS..	109
Nerlynx.....	183	ONETOUCH ULTRASOFT	
NEUTEK 2TEK TEST STRIPS.....	109	LANCETS.....	109
Nexavar.....	254	ONETOUCH VERIO TEST STRIP....	109
Ninlaro.....	160	Onfi oral suspension.....	50
nitrofurantoin macrocrystal.....	121	Onfi oral tablet 10 mg, 20 mg.....	50
nitrofurantoin monohyd/m-cryst.....	121	ON-THE-GO 30G LANCETS	
NON-ASPIRIN CHILD'S DROPS.....	7	GENTLE, 1.5MM.....	109
Norditropin FlexPro.....	251	Opdivo.....	188
NORTEMP 80 MG/0.8 ML DROP.....	7	Opsumit.....	85

OPTIUM EZ TEST STRIP.....	109	PRECISION Q-I-D TEST STRIPS.....	109
OPTIUM TEST STRIP.....	109	PRECISION XTRA TEST STRIPS.....	109
OPTUMRX TEST STRIP.....	109	Premarin oral.....	125
Orencia.....	3	PREMIUM V10 GLUCOSE TEST	
Orencia (with maltose).....	2	STRIP.....	109
Orencia ClickJect.....	3	Premphase.....	125
Orenitram.....	273	Prempro.....	125
Orfadin.....	187	PRENATAL + DHA COMBO PACK..	219
Orkambi.....	170	PRENATAL 19 CHEWABLE	
Otezla.....	23	TABLET (OTC).....	219
Otezla Starter.....	23	PRENATAL FORMULA TABLET ...	219
paroxetine HCl oral tablet.....	137	PRENATAL GUMMIES.....	219
paroxetine HCl oral tablet extended		PRENATAL MULTI + DHA	
release 24 hr.....	137	SOFTGEL P/F, GLUTEN-FREE.....	219
Paxil oral suspension.....	137	PRENATAL MULTIVITAMIN	
PEDIACARE FEVER REDUCER		TABLET.....	219
SUSP.....	7	PRENATAL MULTIVITAMIN-DHA	
PEDIAVENT 1 MG TABLET CHEW...	17	SFGL.....	219
PEDIAVENT 2 MG/5 ML SYRUP.....	17	PRENATAL ONE TABLET.....	219
perphenazine-amitriptyline.....	138	PRENATAL TABLET.....	219
PERRY PRENATAL CAPSULE.....	219	PRENATAL TABLET (OTC).....	219
PHARMACIST CHOICE 30G		PRENATAL TABLET OUTER (OTC)	219
LANCETS ULTRA THIN.....	109	PRENATAL VITAMIN TABLET.....	219
PHARMACIST CHOICE TEST		PRENATAL VITAMINS TABLET	
STRIPS.....	109	PHOSPHORUS FREE.....	219
Phenadoz.....	120	PRESSURE ACTIVATED 21G	
phenobarbital.....	140	LANCETS.....	109
PHENTERMINE 15 MG CAPSULE.....	22	PRESSURE ACTIVATED 28G	
PHENTERMINE 30 MG CAPSULE		LANCETS.....	109
PELLETIZED.....	22	PRO COMFORT 30G LANCETS.....	109
PHENTERMINE 37.5 MG CAPSULE..	22	PRO COMFORT 31G LANCET.....	109
PHENTERMINE 37.5 MG TABLET ...	22	Procrit injection solution 10,000	
PHENYLEPHRINE-PYRILAMINE		unit/mL, 2,000 unit/mL, 20,000 unit/2	
10-25.....	17	mL, 20,000 unit/mL, 3,000 unit/mL,	
PHENYLHISTINE DH LIQUID		4,000 unit/mL, 40,000 unit/mL.....	89
(OTC).....	17	PRODIGY NO CODING TEST	
Plegridy.....	154	STRIPS.....	109
POLY-VITA WITH IRON DROPS.....	209	PRODIGY PRESSURE ACTIVATED	
POLYVITAMIN W-IRON DROPS.....	209	28G.....	109
Pomalyst.....	216	PRODIGY SAFETY 26G LANCETS..	109
Portrazza.....	182	PRODIGY TWIST TOP 28G LANCET	
Praluent Pen.....	13	.....	109
PRECISION PCX PLUS TEST STR....	109	Promacta.....	83
PRECISION PCX TEST STRIPS.....	109	promethazine injection solution.....	120
PRECISION POINT OF CARE STR...	109	promethazine oral.....	120



promethazine rectal.....	120	RA ONE DAILY PRENATAL DHA	
PROMETHAZINE VC-CODEINE		PACK 30'S TAB & 30'S CAP .....	219
SYRUP .....	17	RA PRENATAL TABLET .....	219
PROMETHAZINE-CODEINE		RA SLEEP TABLET .....	20
SYRUP .....	17	RA SLEEP-AID SOFTGEL .....	20
PROMETHAZINE-DM SYRUP .....	17	Radicava .....	77
Promethegan .....	120	Ravicti .....	115
protriptyline .....	138	READYLANCE 21G SAFETY	
PSEUDOEPHED 30 MG/5 ML SOLN..	17	LANCETS .....	109
PSEUDOEPHEDRINE 30 MG		READYLANCE 23G SAFETY	
TABLET .....	17	LANCETS .....	109
PSEUDOEPHEDRINE 60 MG		READYLANCE 26G SAFETY	
TABLET EX-STR, NON DROWSY		LANCETS .....	109
(OTC) .....	17	READYLANCE 28G SAFETY	
PUSH BUTTON SAFETY 21G		LANCETS .....	109
LANCET .....	109	READYLANCE 30G SAFETY	
PUSH BUTTON SAFETY 28G		LANCETS .....	109
LANCET .....	109	Rebif (with albumin) .....	154
PV CHILDREN'S NON-ASA LIQ .....	7	Rebif Rebidose .....	154
PV INFANT NON-ASA 80 MG/0.8		Rebif Titration Pack .....	154
ML ASPIRIN FREE, A/F .....	7	REFUAH PLUS TEST STRIPS .....	109
quinine sulfate .....	223	RELIAMED 30G LANCETS .....	109
QUINTET AC GLUCOSE TEST		RELIAMED SAFETY 23G LANCETS	
STRIPS .....	109	.....	109
QUINTET GLUCOSE TEST STRIPS.	109	RELIAMED SAFETY 28G LANCETS	
RA ACTA-TABS PE TABLET .....	17	LATEX-FREE .....	109
RA ALLERGY MED 25 MG		RELIAMED SAFETY SEAL 28G	
CAPSULE .....	20	LANCT .....	109
RA ALLERGY MED 25 MG TABLET.	20	RELIAMED SAFETY SEAL 30G	
RA ALLERGY MED 25 MG TABLET		LANCT .....	109
COATED MINITABS .....	20	RELION CONFIRM-MICRO TEST	
RA ALLERGY PLUS SINUS		STRP .....	109
TABLET .....	17	RELION MICRO TEST STRIPS .....	109
RA CHILD CETIRIZINE 10 MG		RELION PRIME TEST STRIPS .....	109
CHEW 24 HR,INDOOR/OUTDOOR...	17	RELION THIN 26G LANCETS .....	109
RA E-ZJECT 26G LANCETS .....	109	RELION ULTIMA TEST STRIPS .....	109
RA E-ZJECT 28G LANCETS .....	109	RELION ULTRA THIN PLUS 33G ...	109
RA INFANT FEVER-PAIN REL		RELION ULTRA THIN PLUS	
SUSP .....	7	LANCETS .....	109
RA LORATADINE 10 MG TABLET		Relistor oral .....	173
NON-DROWSY .....	17	Relistor subcutaneous solution .....	172
RA MOTION SICKNESS RLF TB		Relistor subcutaneous syringe .....	172
CHEW RASPBERRY FLAVOR .....	17	Remicade .....	146
RA NON-ASPIRIN 160 MG/5 ML		Remodulin .....	275
CHILDREN'S,CHERRY .....	7	Renflexis .....	148

Repatha Pushtronex.....	97	SM COLD & ALLERGY TABLET.....	17
Repatha SureClick.....	97	SM COLOR LANCETS 21G.....	109
Repatha Syringe.....	97	SM LANCETS 21G.....	109
REVEAL TEST STRIP.....	109	SM NOSE DROPS.....	17
Revlimid.....	163	SM ONE DAILY PRENATAL	
RIGHT STEP PRENATAL VIT TAB..	219	COMBO PK.....	219
RIGHTEST GL300 30G LANCETS.....	109	SM PRENATAL VITAMINS TABLET	
RIGHTEST GS100 TEST STRIPS.....	109	.....	219
RIGHTEST GS250S TEST STRIPS.....	109	SM SINUS AND ALLERGY TABLET	
RIGHTEST GS260 TEST STRIPS.....	109	MAXIMUM STRENGTH.....	17
RIGHTEST GS300 TEST STRIPS.....	109	SM THIN LANCETS 26G.....	109
RIGHTEST GS550 TEST STRIPS.....	109	SMART SENSE COLOR 33G	
RITIFED SYRUP.....	17	LANCETS.....	109
Rituxan.....	231	SMART SENSE STANDARD 21G.....	109
Rituxan Hycela.....	232	SMART SENSE TEST STRIPS	
Rubraca.....	233	PREMIUM, NO CODE.....	109
Rydapt.....	174	SMART SENSE THIN 26G LANCETS	
RYMED TABLET.....	17	.....	109
SAFETY 21G LANCETS LATEX-		SMARTEST LANCET.....	109
FREE.....	109	SMARTEST TEST STRIPS.....	109
SAFETY 28G LANCETS LATEX-		SOFT TOUCH LANCETS.....	109
FREE.....	109	SOLUS V2 28G LANCETS.....	109
SAFETY LANCETS 26G.....	109	SOLUS V2 30G TWIST LANCETS.....	109
SAFETY SEAL 28G LANCETS.....	109	SOLUS V2 AUDIBLE TEST STRIPS..	109
SAFETY SEAL 30G LANCETS.....	109	Sovaldi.....	244
SAFETY-LET 30G LANCETS.....	109	Sprycel oral tablet 100 mg, 140 mg, 20	
Saizen.....	248	mg, 50 mg, 70 mg, 80 mg.....	60
Saizen click.easy.....	248	Stelara intravenous.....	281
Serostim subcutaneous recon soln 4 mg,		Stelara subcutaneous syringe.....	280
5 mg, 6 mg.....	249	STERILANCE TL TWIST 30G	
SILADRYL 12.5 MG/5 ML LIQUID.....	20	LANCET.....	109
SILAPAP INFANT'S DROPS		STERILANCE TL TWIST 32G	
INFANT'S.....	7	LANCET.....	109
sildenafil (antihypertensive) intravenous	208	Stivarga.....	225
sildenafil (antihypertensive) oral.....	207	Strensiq.....	24
Siliq.....	41	STUART ONE CAPSULE.....	219
SIMILAC PRENATAL COMBO		SUDOGEST 30 MG TABLET BOXED..	17
PACK.....	219	SUDOGEST 60 MG TABLET.....	17
Simponi.....	117	SUDOGEST SINUS & ALLERGY	
Simponi ARIA.....	116	TAB.....	17
SINGLE-LET LANCETS.....	109	SUPER THIN 28G LANCETS	
Sirturo.....	31	STERILE.....	109
SM ADULT NASAL		SUPHEDRIN LIQUID.....	17
DECONGESTANT LQ.....	17	SURE COMFORT 18G LANCETS.....	109
SM ALLERGY RELIEF 1.34 MG TAB	17	SURE COMFORT 21G LANCETS.....	109

SURE COMFORT 23G LANCETS.....	109	testosterone transdermal gel in packet...	263
SURE COMFORT 28G LANCETS.....	109	tetrabenazine.....	264
SURE COMFORT 30G LANCETS.....	109	Thalomid.....	265
SURE-LANCE 26G LANCETS.....	109	THERANATAL CORE NUTRITION	
SURE-LANCE FLAT LANCETS.....	109	TAB.....	219
SURE-LANCE THIN 28G LANCETS	109	THERANATAL OVAVITE COMBO	
SURE-LANCE ULTRA THIN 30G.....	109	PACK.....	219
SURE-TEST EASYPLUS MINI STRIP		THERANATAL PLUS COMBO	
.....	109	PACK.....	219
SURE-TOUCH LANCET.....	109	THIN LANCETS 28G.....	109
Surmontil.....	138	TOPCARE UNIVERSAL1 33G	
Sutent.....	255	LANCETS.....	109
Sylatron.....	210	TOPCARE UNIVERSAL1 THIN	
Sylvant.....	241	LANCET ULTRA THIN, 30G.....	109
SymlinPen 120.....	218	Tracleer.....	85
SymlinPen 60.....	218	TRAVEL SICKNESS 25 MG TAB	
Synagis.....	203	CHEW.....	17
Synribo.....	194	TRAVEL-EASE 25 MG TABLET.....	17
Syprine.....	277	Tremfya.....	118
Tafinlar.....	54	tretinoin topical cream.....	269
Tagrisso.....	200	tretinoin topical gel 0.01 %, 0.025 %.....	269
Taltz Autoinjector.....	161	trihexyphenidyl.....	119
Taltz Syringe.....	161	trimipramine.....	138
Tarceva oral tablet 100 mg, 150 mg, 25		TRI-VI-SOL DROPS.....	209
mg.....	88	TRI-VITA DROPS.....	209
Targretin topical.....	36	TRI-VITAMIN DROPS.....	209
Tasigna.....	184	TRUE METRIX GLUCOSE TEST	
TD GOLD TEST STRIP.....	109	STRIP.....	109
Tecentriq.....	28	TRUEPLUS 26G LANCETS.....	109
Tecfidera oral capsule,delayed		TRUEPLUS 33G LANCETS.....	109
release(DR/EC) 120 mg, 120 mg (14)-		TRUEPLUS SAFETY 28G LANCETS	
240 mg (46), 240 mg.....	72	28G, STERILE.....	109
TECHLITE 28G LANCETS.....	109	TRUEPLUS SUPER THIN 28G	
TECHLITE 30G LANCETS.....	109	LANCET 28G, STERILE.....	109
Technivie.....	196	TRUEPLUS ULTRA THIN 30G	
TELCARE TEST STRIPS.....	109	LANCET.....	109
TELCARE ULTRA THIN 30G		TRUETEST GLUCOSE TEST STRIPS	
LANCETS.....	109	.....	109
temazepam oral capsule 15 mg, 30 mg...	139	TRUETEST GLUCOSE TEST STRIPS	
Temodar intravenous.....	260	HRI.....	109
Tencon oral tablet 50-325 mg.....	122	TRUETRACK GLUCOSE TEST	
TEST N'GO GLUCOSE TEST STRIP.....	109	STRIPS.....	109
testosterone cypionate.....	263	Tymlos.....	1
testosterone enanthate.....	263	Tysabri.....	181
testosterone transdermal gel.....	263	Tyvaso.....	274

ULTILET 28G LANCETS.....	109	UNISTIK CZT COMFORT 28G	
ULTILET 30G LANCETS.....	109	LANCET.....	109
ULTILET 33G LANCETS.....	109	UNISTIK CZT NORMAL 23G	
ULTILET BASIC 30G LANCETS.....	109	LANCETS.....	109
ULTILET CLASSIC 26G LANCETS..	109	UNISTIK SAFETY 28G LANCET.....	109
ULTILET CLASSIC 28G LANCETS..	109	UNISTIK SAFETY 30G LANCETS....	109
ULTILET CLASSIC 30G LANCETS..	109	UNISTIK TOUCH 21G LANCETS.....	109
ULTILET CLASSIC 33G LANCETS..	109	UNISTIK TOUCH 23G LANCETS.....	109
ULTILET SAFETY 23G LANCETS...	109	UNISTIK TOUCH 28G LANCETS.....	109
ULTIMA TEST STRIPS.....	109	UNISTIK TOUCH 30G LANCETS.....	109
ULTRA THIN 28G LANCETS		UNISTRIP1 GLUCOSE TEST STRIP..	109
ULTRA THIN.....	109	Unituxin.....	73
ULTRA THIN 31G LANCETS.....	109	UNIVERSAL 1 33G LANCETS FOR	
ULTRA THIN 33G LANCETS.....	109	MEIJER.....	109
ULTRALANCE 26G LANCETS.....	109	Uptravi oral tablet 1,000 mcg, 1,200	
ULTRALANCE 28G LANCETS.....	109	mcg, 1,400 mcg, 1,600 mcg, 200 mcg, 400	
ULTRA-THIN II 26G LANCET.....	109	mcg, 600 mcg, 800 mcg.....	240
ULTRA-THIN II 28G LANCETS.....	109	Uptravi oral tablets,dose pack.....	240
ULTRA-THIN II 30G LANCETS.....	109	VALU-DRYL ALLERGY MED TAB...20	
ULTRATLC LANCETS.....	109	VALU-TAPP DECONGESTANT	
ULTRATRAK TEST STRIP.....	109	DROP.....	17
ULTRATRAK ULTIMATE TEST		VAZOBID-PD SUSPENSION.....	17
STRIPS.....	109	VAZOTAB 10-25 MG TABLET.....	17
UNILET COMFORTOUCH 26G		Velcade.....	38
LANCETS.....	109	Venclexta oral tablet 10 mg, 100 mg, 50	
UNILET COMFORTOUCH LANCET		mg.....	285
.....	109	Venclexta Starting Pack.....	285
UNILET EXCELITE II LANCET.....	109	Verzenio.....	4
UNILET EXCELITE LANCET.....	109	Viekira Pak.....	198
UNILET GP LANCET.....	109	Viekira XR.....	198
UNILET MICRO THIN 33G		Vimizim.....	81
LANCETS.....	109	VINACAL B PRENATAL COMBO	
UNILET SUPER THIN 30G		PACK.....	219
LANCETS SINGLE-USE,STERILE....	109	Vosevi.....	247
UNILET ULTRA THIN 28G		Votrient.....	206
LANCETS.....	109	V-R TRIACTING ORANGE SYRUP... 17	
UNISOM 50 MG SLEEPGELS		WAL-ACT D COLD & ALLERGY	
SOFTGEL.....	20	TAB.....	17
UNISTIK 3 COMFORT LANCET.....	109	WAL-DRYL ALLERGY 12.5 MG/5	
UNISTIK 3 EXTRA 21G LANCETS...109		ML.....	20
UNISTIK 3 GENTLE 30G LANCETS 109		WAL-DRYL ALLERGY 25 MG	
UNISTIK 3 NORMAL 23G LANCETS		CAPSULE.....	20
.....	109	WAL-DRYL ALLERGY 25 MG	
UNISTIK 3 SAFETY 21G LANCETS. 109		MINITAB MINITAB, COATED.....	20

WAL-DRYL-D ALLERGY & SINUS CPT.....	17	Zepatier.....	78
WAL-FEX ALLERGY 180 MG TABLET.....	17	ZEPHREX-D 30 MG TABLET.....	17
WAL-FEX ALLERGY 60 MG TABLET.....	17	Zinbryta.....	57
WAL-FINATE 4 MG TABLET.....	17	zolpidem oral tablet.....	127
WAL-FINATE-D TABLET.....	17	Zomacton.....	248
WALGREENS ULTRA THIN LANCETS.....	109	Zorbtive.....	250
WAL-ITIN 10 MG ODT NON- DROWSY.....	17	Zydelig.....	143
WAL-ITIN 10 MG TABLET NON- DROWSY,24 HR RLF.....	17	Zykadia.....	48
WAL-PHED 30 MG TABLET NON- DROWSY, MAX-STR.....	17	Zytiga.....	5
WAL-PHED PE SINUS-ALLERGY TAB.....	17		
WAL-PHED SINUS AND ALLERGY TAB.....	17		
WAL-SLEEP Z 25 MG ODT.....	20		
WAL-SLEEP Z 25 MG SOFTGEL.....	20		
WAL-SOM 25 MG ODT.....	20		
WAL-SOM 50 MG SOFTGEL SOFTGEL,MAX STRENGTH.....	20		
WAL-TAP ELIXIR.....	17		
WAL-ZYR 10 MG TABLET.....	17		
WAVESENSE JAZZ TEST STRIPS.....	109		
WAVESENSE PRESTO TEST STRIPS .....	109		
Xadago.....	235		
Xalkori.....	53		
Xeljanz.....	268		
Xeljanz XR.....	268		
Xermelo.....	259		
Xifaxan oral tablet 200 mg, 550 mg.....	228		
Xolair.....	195		
Xtandi.....	86		
Xuriden.....	279		
Yervoy.....	156		
Yondelis.....	270		
zaleplon.....	127		
Zebutal oral capsule 50-325-40 mg.....	122		
Zejula.....	186		
Zelboraf.....	284		